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ABSTRACT 
 
The four serotypes of dengue virus (DENV 1-4) have a significant and growing 
impact on global health.  Dengue disease encompasses a wide range of clinical 
symptoms, usually presenting as an uncomplicated febrile illness lasting 5-7 days; 
however, a small percentage of infections are associated with plasma leakage and 
bleeding tendency (called dengue hemorrhagic fever, DHF), which can result in shock.  
Epidemiological studies indicate that severe dengue disease most often occurs during 
secondary heterotypic DENV infection.  Additionally, plasma leakage (the hallmark of 
DHF) coincides with defervescence and viral clearance, suggesting that severe disease 
arises from the immune response to infection rather than a direct effect of the virus.   
A number of studies have found increased levels of markers of immune cell 
activation in patients with DHF compared to patients with the less severe form of disease 
(DF).  These markers include IFNγ, TNFα, soluble CD8, soluble IL-2 receptor, soluble 
TNF receptor, and CD69, which support a role for T cells in mediating 
immunopathology.  Because of the high homology of DENV 1-4, some degree of 
serotype-cross-reactivity is seen for most T cell epitopes.  A high percentage of DENV-
specific T cells recognize multiple DENV serotypes, as demonstrated by peptide-MHC 
(pMHC) tetramer binding and in vitro functional assays performed on PBMC from 
subjects vaccinated with an experimental DENV vaccine or naturally-infected subjects 
with secondary (>1) DENV infection.   
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This thesis sought to address several gaps in the literature, specifically whether T 
cell responses differ in primary versus secondary (natural) infection.  We studied the 
frequency, phenotype, and function of DENV-specific T cells.  We demonstrated 
substantial serotype-cross-reactivity of antigen-specific T cells generated in response to 
naturally-acquired primary as well as secondary DENV infection.  The frequency of A11-
NS3133 epitope-specific T cells during acute infection did not correlate with disease 
severity.  However, the peak frequency occurred earlier in primary infection while the 
frequency of CD45RA+ T cells declined quicker in secondary infection, suggesting the 
expansion of DENV-specific memory T cells.  DENV-immune T cells exhibited different 
functional capabilities that were dependent on the particular serotype of infection.  
Specifically, DENV-1 or -3 stimulation of A11-NS3133 epitope-specific T cell lines 
resulted in robust function that included IFNγ production, whereas DENV-2 stimulation 
resulted in limited function that often included MIP-1β but not IFNγ production.  These 
data support a role for T cells in DENV infection and offer new insights into their 
potential contribution to dengue pathology. 
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CHAPTER I 
INTRODUCTION 
 
A. Global impact of dengue 
 The tropical and subtropical regions of the world are home to an array of diseases 
transmitted by arthropod vectors.  Among them are the dengue viruses (DENV), a 
collection of four related but genetically-distinct viruses (termed serotypes 1-4) which are 
transmitted by mosquitoes and cause disease in nearly half of their infected hosts.  The 
global reach of dengue has expanded dramatically over the past forty years and currently 
extends into >100 countries (World Health Organization, Dengue and Dengue 
Hemorrhagic Fever Fact Sheet, <http://www.who.int/mediacentre/factsheets/fs117/en 
/index.html>).  Approximately 3.6 billion people currently live in areas at risk of DENV 
transmission, resulting in an estimated 70-500 million infections, 2.1 million severe cases 
of disease, and over 20,000 deaths each year (Mark Beatty, Pediatric Dengue Vaccine 
Initiative, Global Burden of Dengue, <http://www.pdvi.org/about_dengue/GBD.asp>).  
The spread of dengue is largely due to increasing globalization and urbanization, which 
allow the principle mosquito vector for DENV, Aedes aegypti, a greater area to establish 
its home (Wilder-Smith and Gubler, 2008).  Increasing global trade and travel provide an 
easy route to physically transport an infected mosquito or the virus itself via infected 
blood (on which mosquitoes feed) to new regions, and densely-populated urban centers 
offer plenty of opportunities for standing water, which serves as a breeding ground for 
the potential DENV vectors.   
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 The transmission cycle of DENV is largely maintained through mosquito-human 
contact (reviewed in Gubler and Kuno, 1997).  The anthropophilic nature of Aedes 
aegypti prompted the species to adapt to human behavior, resulting in its domestication 
and, thus, its role as primary DENV vector.  Other Aedes species also contribute to 
DENV transmission (e.g. A. albopictus), some even sustaining limited sylvatic cycles 
with non-human primates in Africa and Asia (Rodhain, 1991).  Once mosquitoes are 
infected with DENV they are able to transmit the virus throughout the remainder of their 
lifetime, which, according to laboratory tests, may last over 100 days (Gubler, 1970).  
Not only can the vectors pass DENV on to humans, but evidence for vertical and sexual 
transmission amongst the mosquitoes themselves has also been found (Rosen, 1987; 
Freier and Rosen, 1987, 1988).  Transmission efficiency varies according to a number of 
factors including ambient temperature, which affects the duration of gonotrophic cycles, 
frequency of blood meals, and the external incubation period (the time between DENV-
infection of the mosquito and its ability to subsequently pass infectious DENV to 
humans) (Rodhain and Rosen, 1997).  While A. aegypti is largely limited to warm 
tropical and subtropical climates, the less efficient DENV vector A. albopictus can 
withstand lower temperatures.  A. albopictus, which is now established in many parts of 
the continental U.S. and Europe, is also more susceptible to oral DENV infection and can 
become infected on persons with lower viremia levels (Kuno, 1997).  There is no 
evidence of chronic DENV infection in humans; the extent of anthropophilia among 
Aedes species, and the ever-increasing human population, allow for maintenance of 
DENV transmission.   
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 Recent outbreaks of DENV infection have renewed domestic interest in this viral 
threat.  In 2006-2007, significant dengue outbreaks in the Americas affected Mexico, 
Latin America, the Caribbean, and South America with over 1 million reported cases 
(PAHO, 2007).  Outbreaks have occurred in Hawaii (Effler, et al., 2005) and Puerto Rico 
(Rigau-Perez and Laufer, 2006) during the past decade.  DENV has been virtually 
eradicated from the continental U.S. since the 1940s.  However, occasional DENV 
infections have been reported in the southern-most parts of Texas, tracking with 
outbreaks that occurred in nearby Mexican cities (CDC, 1996, 2001, 2007).  Most 
recently, DENV infections have occurred in Key West, Florida, with a seroprevalence of 
about 5% recorded in the local population (CDC, 2010).  If DENV makes its way up the 
Florida coast, its presence would mark its true reestablishment in the continental U.S. 
 With the relatively rapid spread of DENV around the world, there is an increased 
awareness of the economic, not to mention human, cost to society.  A recent report 
assessing the economic burden of DENV on eight countries spanning Asia and the 
Americas estimated that hundreds of millions of U.S. dollars were spent each year to treat 
DENV-infected patients (Suaya, et al., 2009).  Considering that many of the countries 
harboring DENV-infected mosquitoes are developing nations, the cost to an average 
family can be overwhelming.  In addition, mosquitoes tend to migrate within a relatively 
confined area (Harrington, et al., 2005; Mammen, et al., 2008), leading to the possibility 
that multiple family members will become infected, further increasing the expense.  Such 
issues serve to highlight the need for more research on DENV infection and ways to treat 
or prevent disease.   
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B. Dengue disease and treatment 
 Dengue disease ranges in severity and can manifest as a variety of clinical 
symptoms.  The most common form of disease, dengue fever (DF), is typically 
characterized by a high fever, retro-orbital headache and severe myalgias that last for five 
to seven days and are occasionally accompanied by a rash (George, 1997).  Some patients 
suffer from dengue hemorrhagic fever (DHF), a more serious condition in which the 
patient experiences DF symptoms as well as bleeding tendencies and plasma leakage, and 
is at higher risk for developing shock.  According to established World Health 
Organization (WHO) guidelines, DHF is subdivided into four grades of severity based on 
the presence and extent of spontaneous bleeding and shock (WHO, 1997).  The most 
severe cases (grades III and IV) are classified as dengue shock syndrome or DSS.  More 
recent recommendations by the WHO acknowledge the breadth and complexity of 
disease symptoms and simply classify cases of DENV infection as uncomplicated or 
severe (WHO, 2009). 
Several clinical variables are tracked throughout hospitalization of DENV-
infected patients and serve as indicators of disease severity.  Tourniquet tests are 
performed to determine the presence and extent of vascular fragility.  Where resources 
are available, platelet counts are measured daily to check for thrombocytopenia 
(<100,000 platelets/mm3 is a criterion for classification as DHF); elevated aspartate 
aminotransferase (AST) values indicate liver damage.  A ≥20% rise in hematocrit 
compared to baseline and evidence of pleural effusion or ascites are markers of plasma 
leakage, the hallmark of DHF (Nimmannitya, 1987).  The new WHO criteria for severe 
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dengue include some of these measures and are intended to help coordinate case 
reporting world-wide.   
Distinguishing cases of DENV infection from other acute febrile illnesses is 
initially challenging, as many viral infections result in fever as well as head and body 
aches.  As dengue disease progresses, however, indicators such as hemorrhage (including 
a positive tourniquet test), thrombocytopenia, leukopenia and pleural effusion help to 
suggest DENV as the pathological agent (Nimmannitya, 1987; Kalayanarooj, 1999b).  
Further difficulty arises when trying to predict whether a patient will recover without 
complications or suffer DHF upon defervescence.  Severe clinical symptoms indicative of 
DHF (e.g. plasma leakage) occur suddenly and concurrent with viral clearance (Vaughn, 
et al., 1997; Vaughn, et al., 2000), so vigilant monitoring of patients around the time of 
defervescence is critical (Nimmannitya, 1987; Kalayanarooj, 1999a). 
 Unfortunately, no vaccine for DENV is yet available nor is there a specific 
treatment for dengue disease.  However, experienced physicians will closely observe 
hospitalized DENV-infected patients and administer fluid replacement therapy at the first 
sign of plasma leakage (Nimmannitya, 1987; Kalayanarooj, 1999a).  Such aggressive 
intervention has been shown to meaningfully reduce the mortality rate, which can 
otherwise reach up to 20% of patients with DHF (Kalayanarooj, 1999a).  Recent efforts 
to design vaccines effective against all four DENV serotypes are discussed below. 
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C. Characteristics of dengue virus 
 The four serotypes of DENV (DENV 1-4) are members of the virus family 
Flaviviridae (named after the prototype virus, yellow fever) and the genus flavivirus 
(reviewed in Lindenbach, et al., 2007).  Flaviviruses have small, enveloped virions with a 
single-stranded, positive-sense RNA genome that is approximately 11,000 nucleotides 
long.  Members of this genus all share a similar virion structure, which is made up of 
three structural proteins (capsid [C], membrane [M], and envelope [E]).  The genome also 
encodes seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5).  
DENV 1-4 share approximately 70% homology at the amino acid level, depending on 
which proteins are being compared; E is quite variable across serotypes, whereas the non-
structural proteins retain more conserved sequences (Irie, et al., 1989). 
 The DENV virion is composed of a lipid bilayer containing E and M 
glycoproteins which encapsulate the nucleocapsid made up of C protein together with the 
RNA genome.  The envelope protein E facilitates binding to cells and virus fusion with 
the host cell membrane, mediating viral entry into the cell.  While a definitive receptor 
remains elusive, it is known that the cell-surface protein dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) can mediate 
attachment and productive infection (Navarro-Sanchez, et al., 2003; Tassaneetrithep, et 
al., 2003), although DC-SIGN internalization is unnecessary for DENV entry (Lozach, et 
al., 2005).  Once inside a host cell, the low pH of the endocytic compartment allows for 
fusion of the viral and host membranes, releasing the nucleocapsid into the cytoplasm.  
The single-stranded, positive-sense RNA genome is immediately ready for translation 
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and is directed toward the endoplasmic reticulum (ER).  The ten viral proteins are 
translated as a single open reading frame along the ER membrane.  Host and viral 
proteases then cleave the polyprotein to release the individual proteins for further 
processing. 
 The seven non-structural proteins of DENV play a variety of roles involving RNA 
replication (NS1, NS3, NS4a, NS5), virus assembly (likely NS2a and NS3) and serine 
protease activity (NS2b, NS3).  They are also known to interfere with anti-viral immune 
responses of the host, such as type 1 interferon (IFN) signaling (NS2a, NS4a, NS4b).  
NS1 is secreted from the cell during infection, its accumulation in patient sera correlating 
with disease severity (Libraty, et al., 2002b).  Once outside the cell, soluble NS1 can bind 
the plasma membrane of both infected and uninfected cells (Avirutnan, et al., 2007), in 
particular endothelial cells, and thus target them for complement-mediated lysis (Lin, et 
al., 2003).  NS3 has been shown to induce apoptosis in vitro, using NS2b as a cofactor 
(Shafee and AbuBakar, 2003).  NS5 induces the production of interleukin (IL)-8 by 
infected cells, which may increase the spread of the virus by recruiting inflammatory 
target cells to the site of infection (Medin, et al., 2005).  The 5’ and 3’ untranslated 
regions (UTRs) of the viral genome are also involved in efficient DENV infection.  These 
regions form highly conserved stem-loop secondary structures which are important for 
viral replication (Alvarez, et al., 2005a; Alvarez, et al., 2005b; Pankhong, et al., 2009); 
UTR mutations can affect the virulence of progeny virions (Cahour, et al., 1995; Men, et 
al., 1996; Zeng, et al., 1998). 
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DENV can infect a variety of cell types.  In vitro experiments using primary 
human cells have demonstrated the susceptibility of monocytes, macrophages, dendritic 
cells (DC), endothelial cells, and lung epithelium to DENV infection (Avirutnan, et al., 
1998; Huang, et al., 2000; Wu, et al., 2000; Chen and Wang, 2002; Lee, et al., 2007).  
Liver-resident macrophages can also become infected, but no viral progeny are 
subsequently produced (Marianneau, et al., 1999).  Staining of patient tissues from 
autopsy and/or biopsy samples has confirmed the presence of DENV antigen in blood-
resident monocytes, macrophages (from spleen, lung, and liver), skin-resident DC, 
lymphocytes found in the spleen and blood and endothelial cells found in the liver and 
lung (Wu, et al., 2000; Jessie, et al., 2004; Limonta, et al., 2007).  Unfortunately, no 
DENV-infected, immunocompetent animal model accurately exhibits the disease 
observed in humans so tracking virus in vivo during acute infection is a challenge.  
Nevertheless, the above cell types were also shown to be susceptible in DENV-infected 
mice (Chen, et al., 2007; Kyle, et al., 2007; Balsitis, et al., 2009; Zellweger, et al., 2010), 
affording some confidence in these models, which typically result in inconsistent and low 
level infection with few, if any, signs of disease.  The continued development and recent 
successful DENV infection of “humanized” mice appears promising for generating a 
useful animal model for DENV infection (Bente, et al., 2005; Kuruvilla, et al., 2007; 
Jaiswal, et al., 2009; Mota and Rico-Hesse, 2009). 
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D. Risk factors for severe dengue disease 
 One of the earliest descriptions of DHF noted that patients with a secondary-type 
antibody response were at greater risk for developing the severe form of disease than 
those exposed to the virus for the first time (Halstead, et al., 1970).  This observation has 
since been confirmed in many studies of DENV patients from all over the world infected 
with any of the four serotypes (Burke, et al., 1988; Guzman, et al., 1990; Thein, et al., 
1997).  While primary DENV infection results in long-term protective immunity to the 
infecting serotype, it only provides partial and transient protection against the other, 
heterologous, serotypes (Sabin, 1952).  This means that an individual can, in theory, 
experience up to four DENV infections in their lifetime with an increased risk for severe 
disease upon subsequent (secondary) exposure to a heterologous DENV serotype.  Prior 
immunity, therefore, seems to increase the risk for severe dengue disease, implicating a 
role for adaptive immune responses (i.e. T and B cells) in contributing to disease 
pathogenesis.  Details regarding the involvement of these factors are discussed later in 
this chapter. 
 In addition to prior immunity, many other factors also help shape the outcome of 
disease in DENV-infected individuals.  Such influential features include demographic, 
host genetic, and virus-specific factors that demonstrate associations with patients 
experiencing mild versus severe disease.  Each of these elements likely contributes to the 
final outcome of DENV-infected patients, but their extent of involvement in dengue 
pathology remains unclear. 
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i. Demographic factors 
A number of studies have noted that certain demographic populations, unrelated 
to genetic background, are at higher or lower risk for severe dengue disease.  Studies on 
the nutritional status of infants (Nguyen, et al., 2005) and children (Thisyakorn and 
Nimmannitya, 1993) report an underrepresentation of DHF/DSS cases in those with 
malnutrition, and this was attributed to dampened cellular immunity.  This is in contrast 
to another study which demonstrated that, while malnourished children were at lower risk 
of contracting DENV infection, those who did were at higher risk of developing shock 
(Kalayanarooj and Nimmannitya, 2005).  On the other hand, obese children are at higher 
risk of both contracting DENV infection (Kalayanarooj and Nimmannitya, 2005) and 
developing severe disease (Kalayanarooj and Nimmannitya, 2005; Pichainarong, et al., 
2006).  Age appears to influence the symptoms of disease, as one study showed that 
children had a higher incidence of cough and hepatomegaly compared to adults, who 
more often experienced headache, myalgias/arthralgias and petechiae (Wichmann, et al., 
2004).  In other reports, socio-economic status also correlated with severe disease, in 
particular patients from high income or highly educated homes (Blanton, et al., 2008; 
Figueiredo, et al., 2010).  In general, those with chronic disease or other complicating 
factors such as diabetes, allergies, or hypertension are at increased risk for DHF (Bravo, 
et al., 1987; Figueiredo, et al., 2010). 
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ii. Host genetic factors 
 A relatively small fraction (~6% of clinical cases) of DENV-infected individuals 
experiences severe dengue disease (Mark Beatty, Pediatric Dengue Vaccine Initiative, 
Global Burden of Dengue, <http://www.pdvi.org/about_dengue/GBD.asp>) implicating 
host-specific genetic factors in contributing to disease susceptibility.  For example, 
patients with blood type AB were at higher risk for developing DHF compared to those 
with other blood types in studies of Thai children (Kalayanarooj, et al., 2007; Fried, et 
al., 2010).  Race and/or ethnic associations with dengue disease have regularly been 
noted, specifically identifying “white” individuals at higher risk for severe disease than 
“black” individuals (Bravo, et al., 1987; Sierra, et al., 2007b; Figueiredo, et al., 2010).  
These demographic differences may be caused by genetic variations affecting human 
leukocyte antigen (HLA) haplotypes or other genes which affect the immune response to 
DENV infection (Sierra, et al., 2006; Restrepo, et al., 2008).   
A number of studies have linked specific HLA class I, II, and III alleles with 
different dengue disease manifestations.  HLA-A2 is a common class I allele found 
throughout many populations worldwide (The Allele Frequency Net Database 
<http://www.allelefrequencies.net/>) and was found to be associated with clinically 
evident secondary DENV infection in pediatric Thai subjects (Chiewsilp, et al., 1981; 
Stephens, et al., 2002).  More detailed analysis found that HLA-A*0203 in particular 
correlated with mild disease (DF) as compared to HLA-A*0207, which correlated with 
severe disease (DHF) (Stephens, et al., 2002).  This report and others identified 
additional HLA class I and II correlations with protective (HLA-A29, A33, B13, B14, 
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B44, B52, B62, B76, B77, DRB1*04, DRB1*07, DRB1*09) or pathologic (HLA-A1, 
A24, A31, B15, B46, B51, DQ1) outcomes (Chiewsilp, et al., 1981; Paradoa Perez, et al., 
1987; Loke, et al., 2001; LaFleur, et al., 2002; Stephens, et al., 2002; Polizel, et al., 2004; 
Sierra, et al., 2007a; Nguyen, et al., 2008).   
Studies analyzing HLA class III or other genes involved in immune responses, 
including cytokine production, also detected correlations with particular disease 
outcomes.  Separate studies found that the A allele of the single nucleotide polymorphism 
(SNP) at position 308 in the gene for tumor necrosis factor (TNF)α is associated with 
DHF (Fernandez-Mestre, et al., 2004; Perez, et al., 2010).  TNF-308A has been linked to 
higher levels of TNFα protein than other alleles (Wilson, et al., 1997), supporting a role 
for TNFα in dengue pathogenesis.  These same studies also reported that particular SNP 
alleles of the gene for IL-10, which are associated with low levels of IL-10 protein 
production, correlate with DHF (Fernandez-Mestre, et al., 2004; Perez, et al., 2010).  
These groups suggested that high TNFα/low IL-10 production helped mediate severe 
dengue disease.  Another study reported a strong genetic linkage between the SNP allele 
–238A in the TNFα gene and the lymphotoxin-α (LTA)-3 haplotype, which is associated 
with high TNFα and LTα production during acute viremia in DENV-infected patients 
(Gagnon, et al., 2002; Vejbaesya, et al., 2009).  Patients with TNF –238A and LTA-3 
were at greater risk for developing DHF compared to DF, and DHF patients with these 
alleles were nearly all shown to have HLA-B48 and/or HLA-B57 (Vejbaesya, et al., 
2009), otherwise rare HLA haplotypes in this (Thai) population (Stephens, et al., 2002).  
Such analyses underscore the need to address extended haplotypes in future genetic 
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studies of dengue patients in order to better understand potential mechanisms for the 
immunopathology observed in DENV infection.  Additional genes with allelic variants 
associated with different dengue disease outcomes include those for mannose-binding 
lectin (Acioli-Santos, et al., 2008), the vitamin D receptor, Fcγ receptor II (Loke, et al., 
2002), transporter associated with antigen processing, human platelet antigens 
(Soundravally and Hoti, 2007), and DC-SIGN (Sakuntabhai, et al., 2005). 
 
iii. Viral factors 
 As an accurate animal model of dengue disease remains to be established, 
differences in virulence among various virus strains are explored by isolating viruses 
from viremic patients, comparing the viral sequences, and associating specific sequence 
mutations with the patients’ final outcome (Rico-Hesse, 2003).  Most viral isolates come 
from those who are ill enough to come to medical attention, which is a limitation of this 
approach; however, significant correlations have been made.  For example, large 
outbreaks of severe disease are often associated with DENV serotypes 2 and 3, whereas 
DENV-4 is less commonly detected in clinically evident cases of dengue and then mostly 
in those with secondary DENV infections (Nisalak, et al., 2003; Fried, et al., 2010).  
DENV-2 is also more often seen in patients experiencing a secondary DENV infection 
than in those with primary infections.  On the other hand, DENV-1 and DENV-3 cause 
clinically evident dengue in those with either primary or secondary DENV infections.   
Certain serotypes of DENV have also been correlated with particular disease 
symptoms.  One study comparing DENV-2 versus DENV-3 infection in adults from 
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Taiwan found that DENV-3 tended to cause myalgias, ascites and skin rash whereas 
DENV-2 infection was more often associated with bone pain (Tsai, et al., 2009).  A 
different study in Thai children found more pleural effusions and a higher incidence of 
ascites in subjects infected with DENV-2 compared to other serotypes (Fried, et al., 
2010). 
Furthermore, phylogenetic analysis of different virus isolates has identified 
several viral genotypes within each DENV serotype.  For example, DENV-2 (the most 
well studied serotype due to its wide transmission pattern) comprises four genotypes, 
including those that originated in West Africa, the Americas, Southeast Asia and 
Malaysia/Indian subcontinent (Rico-Hesse, et al., 1998; Rico-Hesse, 2003).  West 
African viruses are thought to have the lowest epidemiological impact due to their 
sequence proximity to sylvatic viruses and relatively rare encounter by humans.  
American and Malaysian/Indian viruses are typically associated with cases of DF, 
whereas DHF cases are associated with Southeast Asian viruses (Rico-Hesse, et al., 
1997).  The Southeast Asian viral strains seem to be replacing other DENV-2 genotypes 
worldwide, possibly due to a greater ability to replicate in both mosquito vectors and 
primary human DC, higher infection efficiency (of mosquitoes themselves), and thus 
higher transmission rates (Armstrong and Rico-Hesse, 2001, 2003; Cologna, et al., 2005; 
Anderson and Rico-Hesse, 2006).  Differences in virulence among the different 
genotypes of DENV-2 have been attributed to particular nucleotide changes and RNA 
folding patterns in the 5’ and 3’ UTRs of the virus as well as amino acid changes in a 
variety of viral proteins (Leitmeyer, et al., 1999).  Replacement of the 5’ and 3’ UTRs 
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together with amino acid 390 of E protein in a Southeast Asian virus with those found in 
an American strain lowered the level of replication of the virus in primary human DC 
cultures to that seen for the wild-type American virus (Cologna and Rico-Hesse, 2003).  
This resulted in a 10-fold decrease in viral yield compared to the wild-type Southeast 
Asian virus.  Higher viral loads are often associated with more severe disease (Murgue, et 
al., 2000; Vaughn, et al., 2000; Libraty, et al., 2002a; Libraty, et al., 2002b), though this 
pattern is not always seen (Sudiro, et al., 2001).  Genotype classification of serotypes 1, 
3, and 4 is less well established, although Southeast Asian strains of DENV-3 have been 
associated with large DHF outbreaks (Chungue, et al., 1993; Rico-Hesse, 2003).  DENV-
3 strains from the Indian subcontinent have been shown to evolve to become more 
virulent (Lanciotti, et al., 1994), and American strains are associated with outbreaks of 
milder disease (Rico-Hesse, 2003).  Studies like that coordinated by the Broad Institute 
(of Massachusetts Institute of Technology and Harvard University) intend to vastly 
increase the database of DENV sequences in order to assess viral diversity across 
continents as well as within infected individuals (Broad Institute, Dengue Virus Portal, 
<http://www.broadinstitute.org/annotation/viral/Dengue/>).  Such analyses should help 
identify specific elements of the virus that contribute to mild versus severe disease. 
 
E. DENV vaccine initiatives 
 Considering the potential for all four DENV serotypes to cause severe disease, 
and the increased risk for severe disease in secondary heterologous DENV infection, 
strategies for developing a DENV vaccine have been directed at achieving tetravalent 
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immunity (Webster, et al., 2009).  Numerous strategies are currently being enlisted to 
develop live-attenuated, inactivated, chimeric, infectious clone, and/or subunit vaccines.  
Several vaccine candidates are now in various stages of clinical trials due to the efforts of 
investigators at Walter Reed Army Institute of Research (WRAIR), GlaxoSmithKline 
(GSK), Acambis/Sanofi Pasteur (SP), and the National Institutes of Health (NIH), among 
others.   
Live-attenuated vaccines have several theoretical advantages over other strategies 
including efficacy, cost, and long-term immunity (Webster, et al., 2009).  The yellow 
fever virus vaccine YF-17D is a live-attenuated virus that has proven to be extremely 
effective at inducing robust T and B cell responses (Poland, et al., 1981; Akondy, et al., 
2009) and serves as a model for successful vaccines.  SP researchers used the YF-17D 
genome as a backbone into which the coding sequences for the precursor form of M 
(preM) and E proteins from each of the four DENV serotypes were placed (Guirakhoo, et 
al., 2000; Guirakhoo, et al., 2001).  These live, chimeric viruses were genetically stable, 
immunogenic, and provided protection from subsequent DENV challenge in non-human 
primates.  Clinical trials in humans have demonstrated high seroconversion rates among 
various populations, including adults from the U.S.A., children from Mexico, and 
flavivirus-immune individuals from the Philippines (Lang, 2009).  Vaccination induced 
DENV-specific neutralizing antibodies (Guirakhoo, et al., 2006) as well as IFNγ+CD8+ T 
cell responses (thought to be a measure of protection) toward all four serotypes (Guy, et 
al., 2008).  This promising vaccine is currently in Phase IIb efficacy trials in a region of 
Thailand with high DENV incidence.  Live-attenuated versions of DENV have also been 
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developed by serial passage in cell culture.  One such vaccine, developed by WRAIR and 
subsequently licensed to GSK, induced tetravalent neutralizing antibody responses in a 
small pediatric cohort (Simasathien, et al., 2008), but further development is currently on 
hold.  The NIH attenuated DENV by deleting 30 nucleotides from the 3’ UTR of DENV-
1 and -4 and by replacing the preM and E coding sequences of the attenuated DENV-4 
with those from DENV-2 or -3 (Men, et al., 1996; Whitehead, et al., 2003a; Whitehead, 
et al., 2003b; Blaney, et al., 2004).  The monovalent vaccines were immunogenic in 
small cohorts of healthy American adults (Durbin, et al., 2001; Durbin, et al., 2005; 
Durbin, et al., 2006a; Durbin, et al., 2006b), and a tetravalent formulation containing all 
four viruses induced neutralizing antibodies to all four DENV serotypes in rhesus 
monkeys (Blaney, et al., 2005).  A Phase I clinical trial of this vaccine is currently 
underway. 
 
F. T cell cross-reactivity 
 T cells ‘see’ antigen via their T cell receptors (TCR), which bind to class I or 
class II major histocompatibility complexes (MHC) presenting an immunogenic peptide 
(pMHC) usually 8-12 amino acids in length (reviewed in Janeway, 2005).  TCR-pMHC 
binding is considered highly specific, and T cell coreceptors (i.e. CD4 and CD8) act to 
enhance this interaction through direct contact with the MHC itself.  The concept of T 
cell cross-reactivity, or ‘polyspecificity’, refers to the ability of a T cell, expressing a 
single TCR that is defined as specific for a particular pMHC, to engage and respond to a 
different pMHC (Wucherpfennig, et al., 2007).  An increasing body of evidence indicates 
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that while TCR-pMHC interactions are specific (i.e. only recognize a fraction of available 
ligands), an extraordinary amount of cross-reactivity exists in nature.  Mathematical 
calculations predict that a single TCR can bind at least 106 different pMHC complexes 
(Mason, 1998).  The presence of such degeneracy is thought to be necessary to 
accommodate the myriad epitopes (~5x1011 just for 9mer peptides) confronted 
throughout a human lifetime by the relatively limited number of T cells (~1012 total) that 
circulate in a given individual (Wucherpfennig, et al., 2007). 
 T cell cross-reactivity can occur via a number of mechanisms related to the 
interaction between TCRs and pMHC molecules (Yin and Mariuzza, 2009).  TCRs are 
heterodimers consisting of α and β chains, which are generated by rearrangement of 
multiple gene segments (including V, J, D, and C segments) and tested for self-reactivity 
by positive and negative selection in the thymus (Janeway, 2005).  During gene 
rearrangement, TCRs are also subject to random insertions of nucleotides between the 
gene segments of each chain that serve to ultimately increase the diversity of the TCR 
repertoire.  The most variable region of the TCR comprises the complementarity-
determining region (CDR)3 loop, which sits in the middle of the pMHC binding site.  
The flexibility of the CDR3 loop allows for the TCR to adjust to fit the particular pMHC 
complex that is bound (Armstrong, et al., 2008); this is the ‘induced fit’ mechanism of 
cross-reactivity (Yin and Mariuzza, 2009).  Other mechanisms include differential TCR 
docking, structural degeneracy, molecular mimicry, and antigen-dependent tuning of 
pMHC flexibility.  The variety of peptide ligands and the role of T cell cross-reactivity in 
immunity are discussed further below. 
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G. T cell signaling – an overview 
The engagement of a TCR by a pMHC complex initiates a series of protein 
phosphorylation events that culminates into the T cell effector response (reviewed in 
Cisznak, et al., 2007).  The TCR is associated with the CD3 complex on the surface of T 
cells, which includes the γ, δ, ε, and ζ chains that contain immunoreceptor tyrosine-based 
activation motifs (ITAMs).  Although the events that immediately follow TCR-pMHC 
engagement are still unclear, the ITAMs of the CD3 complex become phosphorylated 
(Figure 1.1).  The extent of CD3ζ phosphorylation (CD3ζ is a homodimer, each with 
three ITAMs) determines the number of binding sites for Zap70, which harbors an SH2-
domain.  Upon binding, Zap70 becomes itself phosphorylated and thus activated.  
Activated Zap70 uses its kinase activity to subsequently phosphorylate and activate other 
proteins, including LAT and SLP-76, which continue the phosphorylation cascade.  Two 
major pathways are involved, which ultimately activate transcription factors that will 
initiate the transcription of immune response genes.  Phosphorylated SLP-76 activates 
phospholipase Cγ1 (PLCγ1), which cleaves phosphatidylinositol bisphosphate (PIP2) into 
diacylglycerol (DAG) and inositol trisphosphate (IP3).  IP3 up-regulates the 
concentration of intracellular calcium, helping to activate calcineurin, which leads to 
NFAT activation.  DAG together with calcium activates protein kinase C (PKC), leading 
to NFkB-mediated transcription.  Phosphorylated SLP-76 also activates the MAP kinase 
pathway via Ras, leading to AP-1 activation.  The interaction of these transcription 
factors with their target genes, as well as with each other, leads to an effector response  
FIGURE 1.1. TCR signal transduction pathways. 
Following TCR engagement, members of Src family kinases, Lck and Fyn, are activated, leading
to the phosphorylation of tandemly arranged tyrosine residues within the ITAMs of the CD3 γ, δ, ε, 
and ζ chains. Phosphorylated ITAMs in the CD3 γ, δ, ε, and ζ chains function as docking sites for 
the recruitment of ZAP-70, which subsequently phosphorylates an adapter protein, such as LAT 
and SLP-76. The phosphorylation of adapter proteins initiates the Ras/Raf/MAPK (ERK) and 
PLCγ1/calcineurin/calcium pathways and promotes the formation of the SLP-76-Vav-Nck-Pak1 
complex, which may be important in the regulation of cytoskeletal rearrangements. Sustained 
activation of these pathways is required for transactivation of the transcription factor AP-1 
complex and NF-AT, leading to IL-2 production, T cell proliferation, and effector responses. LAT: 
linker for the activation of T cells; SLP76: Src homology 2 (SH2)-domain-containing leukocyte 
protein-76; PLC-γ1: phospholipase Cγ1; PIP2: phosphatidylinositol 4,5 bisphosphate; IP3: inositol
3,4,5 trisphosphate; PKC: protein kinase C; DAG: diacylglycerol; Grb2: growth-factor-receptor-
bound protein 2; SOS: Ras GTPase guanine nucleotide exchange factor; GADS: Grb2-related 
adapter protein; MAPK: mitogen-activated protein kinase; ERK: extracellular signal-regulated
kinases; NFATc: nuclear factor of activated T cells; AP-1: activating protein 1; NFκB: nuclear 
factor-κB; IκB: inhibitor of nuclear factor-κB.
This figure was reprinted with permission from Cisznak, et al., 2007.
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specific for a given stimulus.  Changes in the strength and/or type of signal, which 
involves not only TCR engagement but coreceptor engagement and cytokine signaling, 
can affect the T cell response.  
 
H. Altered peptide ligands 
The epitopes to which a particular T cell responds are numerous and can differ in 
their primary structure by one or many amino acids.  Early biochemical studies used 
amino acid substitutions of immunogenic peptides to assess the contribution of particular 
amino acid positions to recognition by T cells.  These substituted peptide variants were 
termed altered peptide ligands (APL) and shown to induce T cell responses that often 
differed from T cell recognition of the originally-identified, cognate peptide (Evavold, et 
al., 1993a).  For instance, APL stimulation of a CD4+ T cell clone induced cytolysis and 
up-regulation of surface IL-2 receptors but not proliferation or cytokine production, as 
seen for the cognate ligand (Evavold, et al., 1993b).  In addition, viral isolates from 
chronically-infected patients demonstrated the dose-dependent capacity of naturally-
derived APL to inhibit the cytotoxic T cell response elicited by the original epitope ligand 
(Bertoletti, et al., 1994; Klenerman, et al., 1994).  Classes of APL were subsequently 
characterized according to the T cell response they elicited relative to the cognate 
peptide: agonists (those that elicited a similar response as the cognate ligand), super-
agonists (those that elicited a stronger response), partial agonists (those that elicited a 
weaker or altered response), and antagonists (those that disrupted T cell responses). 
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The mechanism of partial agonism was found to encompass a “continuum of T 
cell signaling” (Evavold, et al., 1993a), covering a spectrum between agonism and 
antagonism, which affected both the quality and quantitative threshold of TCR-mediated 
signaling.  Partial agonist ligands impact early events in T cell signaling that propagate 
through to altered effector responses.  For example, agonistic stimulation of a murine 
CD4+ T cell clone resulted in full phosphorylation of CD3ζ that showed a band of about 
21kDa on a Western Blot, whereas stimulation with a partial agonist resulted in a large 
band at 18kDa (indicating partial phosphorylation of the CD3ζ homodimer) and less of 
the 21kDa band (Sloan-Lancaster, et al., 1994).  This was confirmed by another group 
which also demonstrated that partial agonist stimulation of a murine CD4+ T cell clone 
failed to phosphorylate CD3ε (Madrenas, et al., 1995).  Both groups found that these 
altered phosphorylation states affected the recruitment and activation of Zap70.  A 
separate study showed that the intracellular calcium flux induced by partial agonist 
stimulation reached lower levels and was sustained for a shorter period of time compared 
to that measured after stimulation with an agonist ligand (Sloan-Lancaster, et al., 1996).  
These results highlight the fact that partial agonists affect both the strength and type of 
signal they send through the TCR in order to fine tune their ultimate effect on T cell 
responses. 
 
I. Sequential heterologous infections 
Relatively recent data have demonstrated a significant role for cross-reactive T 
cells that recognize naturally-occurring APL in both murine models and human instances 
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of sequential infection with unrelated pathogens (Welsh, et al., 2010).  Mice immune to 
lymphocytic choriomeningitis virus (LCMV) or Pichinde virus (PV) clear virus more 
quickly upon subsequent infection with doses of vaccinia virus (VV) that are lethal in 
naïve mice (Selin, et al., 1998).  This protection was shown to be mediated by LCMV- or 
PV-specific memory T cells that responded to VV epitopes.  Interestingly, while LCMV-
immune mice quickly cleared VV upon challenge, they also developed acute fat necrosis 
(Yang, et al., 1985; Selin, et al., 1998), an immunopathological condition mediated by 
enhanced IFNγ levels circulating in these mice.  This condition was not detected after VV 
challenge of PV-immune mice, however (Selin, et al., 1998), indicating that not all cross-
reactive T cell responses are equal. 
In humans, human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-
specific T cell responses have been found in HIV and HCV seronegative individuals 
(Kaul, et al., 2001; Wedemeyer, et al., 2001).  These analyses may be identifying cross-
reactive memory T cells generated in response to previous, unrelated infections, which 
may mediate protection from HIV or HCV infection in high risk individuals (Welsh and 
Selin, 2002).  In contrast, HCV patients with severe manifestations of disease were found 
to have a high frequency of epitope-specific CD8+ T cells which were functionally cross-
reactive with an influenza virus epitope (Urbani, et al., 2005).  These cross-reactive T 
cells were not detected in patients with milder disease, suggesting that reactivation of 
memory influenza virus-specific T cells during acute HCV infection contributes to 
immunopathology.  Similarly, particular Epstein Barr virus (EBV)-specific T cell 
responses (compared to other EBV-, human cytomegalovirus- or influenza virus-specific 
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T cell responses) were found to be higher in patients with multiple sclerosis compared to 
healthy EBV-infected individuals (Lunemann, et al., 2010). 
In all of these cases, heterologous immunity mediated by T cells cross-reactive to 
unrelated viruses heavily influenced the outcome of infection.  DENV has multiple 
closely-related serotypes which co-circulate, and infection results in a spectrum of 
clinical manifestations; therefore, it is easy to speculate that serotype-cross-reactive 
memory T cells play a role in shaping the course of disease. 
 
J. Cytokines and disease 
 As T cells respond to an invading pathogen, they exhibit a range of effector 
functions, including cytotoxicity and cytokine production.  These responses serve to 
eliminate the pathogen and prevent or mitigate symptoms of disease experienced by the 
host.  However, as noted above, T cell effector responses themselves can sometimes 
cause or exacerbate disease.  Such instances often occur due to unchecked cytokine 
production. 
T cells produce multiple cytokines upon activation, including IFNγ, MIP-1β, and 
TNFα.  IFNγ is one of the most common cytokines utilized to identify antigen-specific T 
cell responses.  The expression of IFNγ often correlates with protection from viral or 
bacterial infections.  For example, preexisting IFNγ responses to mycobacterial antigens 
correlated with protection from subsequent HIV-related tuberculosis in adults from 
Tanzania (Lahey, et al., 2010).  In contrast, during chronic HCV infection, IFNγ+CD8+ T 
cells contribute to the development of hepatitis (Thimme, et al., 2001), similar to the 
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immunopathology observed after VV challenge of LCMV-immune mice (Yang, et al., 
1985; Selin, et al., 1998), as mentioned above.   
Macrophage inflammatory protein (MIP)-1β is a chemoattractant that recruits 
pro-inflammatory cells (e.g. T cells, macrophages, DCs) that express its receptor, CCR5, 
to the site of infection, thus orchestrating localized immune responses (Maurer and von 
Stebut, 2004).  By way of binding CCR5, MIP-1β has also been shown to interfere with 
HIV infection, which uses CCR5 as a co-receptor for entry into target CD4+ T cells 
(Lehner, 2002).  The production of MIP-1β by T cells seems to require a low threshold 
for activation, leading some to suggest that it is a better marker of antigen-specific T cells 
than IFNγ (De Rosa, et al., 2004; Betts, et al., 2006).   
TNFα can also contribute to both protective and immunopathologic responses.  In 
general, TNFα helps contain localized infections (Janeway, 2005).  However, systemic 
release of TNFα, or its overproduction, can lead to septic shock (Tracey and Cerami, 
1993; Janeway, 2005).  TNFα has also been implicated as a critical mediator of 
inflammatory responses in autoimmune diseases, such as rheumatoid arthritis (Maini, et 
al., 1995).  IFNγ, MIP-1β, and TNFα, together with IL-2 and other cytokines, contribute 
to the T cell response toward countless immunological insults.  Whether individual 
cytokines will contribute to protection or immunopathology (or both) is determined by 
the timing, magnitude, location, and interaction of cytokine responses.   
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K. Identification of virus-specific memory T cells 
In a typical acute infection, innate immunity first responds to non-specific 
features of the invading pathogen in an effort to slow its spread.  Soon thereafter, the 
pathogen-specific adaptive immune response initiates and takes over to clear the 
pathogen from the host.  One of the unique features of adaptive immunity is its ability to 
generate memory to particular pathogens.  Memory T cells have lower thresholds for 
activation and are quicker to respond than naïve T cells (Pihlgren, et al., 1996; 
Curtsinger, et al., 1998; Cho, et al., 1999; Veiga-Fernandes, et al., 2000); thus, they are 
important for limiting the impact of recurrent pathogens over the lifetime of the host.   
Identifying antigen-specific memory T cells, however, has been a challenge.  
Early studies indicated that different isoforms of CD45 could differentiate between naïve 
and memory T cell subsets.  Specifically, CD45RA marked naïve T cells, whereas 
CD45RO was expressed by memory T cells (Young, et al., 1997).  Another study soon 
identified a lymph node homing marker, CCR7, which further stratified memory T cells 
into central memory (CCR7+CD45RA-) and effector memory (CCR7-CD45RA-) 
phenotypes (Sallusto, et al., 1999).  This same study also noticed that CD8+ T cells had a 
third memory subset (CCR7-CD45RA+), which they and others suggested was terminally 
differentiated due to loss of the T cells’ proliferative potential (Sallusto, et al., 1999; 
Champagne, et al., 2001).  However, recent data indicated that these cells are, in fact, 
fully functional (Miller, et al., 2008; Akondy, et al., 2009).  CD127, the IL-7 receptor α 
chain, has been used as a marker of quality memory after murine studies revealed its 
utility in identifying long-lived memory T cells (Kaech, et al., 2003).  Studies assessing 
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antigen-specific CD8+ T cells over the course of acute infection and convalescence in 
humans indicated that CD45RA, CCR7, and CD127 were down-regulated to various 
extents during acute infection and were re-expressed in memory T cells following distinct 
kinetics (Miller, et al., 2008; Akondy, et al., 2009).  Independent re-expression of these 
markers was suggested to reflect a gradual and continuous process of T cell 
differentiation into memory.  While these markers are commonly utilized in studies 
characterizing memory T cells, their ability to identify specific T cell subsets appears to 
be dependent on the model employed for experimentation as well as the particular 
combination of these and other markers that are used.  Thus, the strategy for identifying 
memory T cells continues to be refined. 
 
L. Protective immune responses to DENV infection 
 Infection with one DENV serotype is thought to confer life-long protection from 
re-challenge with that same serotype.  Mechanisms of immune protection are difficult to 
ascertain in DENV-infected patients due to the complexity of delineating protective 
versus pathologic immune responses, among other challenges.  Nonetheless, analyses of 
patient sera have shown that the neutralizing antibody response comprises antibodies that 
block DENV attachment (He, et al., 1995).  This is consistent with findings in mice in 
which anti-E antibodies inhibit viral binding (Roehrig, et al., 1998) and, when passively 
transferred to mice, provide protection from subsequent DENV challenge (Kaufman, et 
al., 1987).  Antibodies specific for preM and NS1 proteins have also been shown to 
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provide protection from DENV challenge in mouse models (Henchal, et al., 1988; 
Kaufman, et al., 1989).   
The role of T cells in mediating protection from DENV infection is somewhat 
more complicated.  DENV infection of IFNα/β receptor knockout mice demonstrated 
higher viral loads upon depletion of CD8+ T cells (Yauch, et al., 2009) but not after 
depletion of CD4+ T cells (Yauch, et al., 2010).  Additionally, immunization of the mice 
with CD8+ or CD4+ epitopes enhanced viral clearance upon subsequent DENV challenge, 
supporting a protective role for T cells.  A similar result was seen after lethal DENV 
challenge of DENV-immunized BALB/c mice, shown to provide 100% protection, which 
demonstrated increased mortality after depletion of CD8+ T cells (Gil, et al., 2009).  
However, a different mouse model (HepG2-grafted SCID) suggested that DENV-specific 
CD8+ T cells have both protective and pathogenic roles (An, et al., 2004).  Specifically, 
mice inoculated with DENV-specific CD8+ T cells and subsequently challenged with a 
lethal dose of DENV showed reduced mortality compared to uninoculated mice (80% 
versus 100%), but the mice that died did so much more quickly (day 12.8 versus day 
17.4).   
The studies above examined mechanisms of protective immunity in mouse 
models during primary DENV infection or upon homologous virus re-challenge.  A 
different study considered the immune response to heterologous DENV infection and 
used IFNα/β and -γ receptor knockout mice to demonstrate with adoptive transfer 
experiments that serotype-cross-reactive antibody was more widely protective compared 
to cross-reactive cell-mediated immune responses (Kyle, et al., 2008).  In general, while 
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T cells likely contribute to protective immune responses by viral clearance and 
enhancement of B cell responses, the antibody response seems to play a greater role in 
mediating protection from DENV infection. 
 
M. Immunopathological mechanisms in dengue pathogenesis 
 Severe dengue disease (DHF/DSS) is characterized by plasma leakage, a 
phenomenon that involves increasing the permeability of capillaries such that blood and 
plasma can leak into body cavities.  However, pathological studies indicate that vascular 
endothelial cells are relatively structurally intact in DHF/DSS patients (Sahaphong, et al., 
1980; Kurane and Ennis, 1992).  Since dengue patients typically experience a rapid 
recovery, it is thought that plasma leakage occurs due to endothelial cell malfunction 
rather than lysis of infected endothelial cells (Kurane and Ennis, 1992).  Thus, DHF-
associated plasma leakage is hypothesized to occur as a result of excessive cytokine 
levels circulating in DHF/DSS patients, which are produced by highly activated immune 
cells triggered by high viral loads (Mathew and Rothman, 2008).  The precise etiology of 
this vascular leak syndrome is under intense investigation, which has led to two 
prevailing, but not mutually exclusive, hypotheses: antibody-dependent enhancement and 
altered cytokine production by serotype-cross-reactive T cells.  Considering the markedly 
increased risk for severe disease in secondary heterologous DENV infection, these 
models assume a role for preexisting adaptive immune responses.  
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i. Antibody-dependent enhancement 
Epidemiological studies on dengue in Thailand in the 1960s first noted two 
populations of patients that experienced DHF: infants with primary DENV infections and 
children with secondary DENV infections (Halstead, et al., 1969; Nimmannitya, et al., 
1969; Halstead, et al., 1970).  Both groups would be expected to have preexisting DENV-
specific antibodies, as infants born to DENV-immune mothers acquire maternally-
derived antibodies in utero and children with secondary infections have antibodies from 
their first DENV infection.  This led researchers to consider a pathogenic role for 
serotype-cross-reactive anti-DENV antibodies in facilitating severe dengue disease via 
antibody-dependent enhancement (ADE) (Halstead, 1970; Halstead and O'Rourke, 1977).  
ADE involves antigen-specific, though sub-neutralizing, antibodies which attach to the 
virus and increase uptake into Fc receptor-bearing cells, thereby increasing the viral load. 
 In vitro experiments that pre-incubated monocytes with immune sera containing 
anti-flavivirus antibodies, then infected the cells with DENV-2, demonstrated higher viral 
titers compared to infection without immune sera (Halstead, et al., 1980).  This was 
supported by later experiments showing in vivo antibody-mediated enhancement of 
DENV infection in rhesus monkeys (Goncalvez, et al., 2007).  In keeping with the 
decline in levels of passively-transferred maternal antibodies over time, clinical studies 
have demonstrated a correlation between the lowered neutralization activity of maternal 
antibody and the infant age at the time of DENV infection (Kliks, et al., 1988; Libraty, et 
al., 2009).  The ability of antibody-containing sera to enhance in vitro infection of 
susceptible cells was also correlated with the age of onset of infant DHF (Chau, et al., 
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2008; Libraty, et al., 2009), supporting a role for ADE in DHF pathogenesis.  In addition, 
some prospective studies noted a correlation between low preexisting neutralizing anti-
DENV antibody titers (Endy, et al., 2004), or high preexisting enhancing antibody titers 
(Kliks, et al., 1989), and the severity of disease experienced during subsequent DENV 
infection of Thai children.  However, a study that compared infants with DF to those with 
DHF detected no differences between these groups in either the neutralizing or enhancing 
activity of maternal antibody (Libraty, et al., 2009).  In support of this, a study assessing 
the enhancing activity of patient sera obtained prior to secondary infection detected no 
correlation with the severity of disease experienced by these individuals upon subsequent 
DENV infection (Laoprasopwattana, et al., 2005).  These data suggest that factors other 
than, or in addition to, ADE contribute to DHF pathogenesis. 
 
ii. Altered cytokine production by serotype-cross-reactive T cells 
Analysis of sera from DENV-infected patients revealed the presence of a number 
of immune cell activation markers.  IFNγ and IL-2 were highly produced during DENV 
infection, and their levels in serum peaked just before the onset of plasma leakage in 
subjects with DHF (Kurane, et al., 1991).  Soluble IL-2 receptors were also found in the 
sera of dengue patients, with higher levels detected in those with DHF versus those with 
DF (Kurane, et al., 1991; Green, et al., 1999b; Libraty, et al., 2002a).  TNFα is a 
cytokine known to cause capillary leakage syndrome (Tracey and Cerami, 1993), and its 
levels were consistently higher in patients experiencing more severe dengue disease 
(Hober, et al., 1993; Kuno and Bailey, 1994; Bethell, et al., 1998; Green, et al., 1999b).  
 32 
Soluble TNFα receptor II was also more abundant in the sera from DHF versus DF 
patients, and its levels showed a positive correlation with the extent of plasma leakage 
and corresponding outcome of DSS versus DHF without shock (Hober, et al., 1996; 
Bethell, et al., 1998; Green, et al., 1999b; Libraty, et al., 2002a).  These molecules 
implicated a role for immune cell activation in dengue pathogenesis, although their 
production could have originated from a variety of immune cell types.  However, levels 
of soluble CD4 were elevated in the sera of DENV-infected individuals, implicating a 
specific role for CD4+ T cells (Kurane, et al., 1991).  Soluble CD8 was significantly 
higher in those experiencing DHF compared to those with DF or those with other, non-
dengue, febrile illnesses (Kurane, et al., 1991; Green, et al., 1999b).  This suggested an 
expressly pathogenic function for CD8+ T cells.  A higher frequency of activated T cells 
(CD69+CD8+) was detected in patients with DHF versus DF (Green, et al., 1999a).  
Taken together, the timing of these responses, with their peak coincident with viral 
clearance and one or two days before the onset of plasma leakage, implicated the immune 
response, and that specifically of T cells, in contributing to dengue pathology (Kurane 
and Ennis, 1992).   
How T cells contribute to DHF pathogenesis is still a matter of debate, but 
investigators suggested that ‘original antigenic sin’ plays a role in secondary 
heterologous DENV infection (Mongkolsapaya, et al., 2003; Welsh and Rothman, 2003).  
This concept, as it refers to T cells, implies that the DENV-specific memory T cell 
repertoire generated in response to a primary infection contains T cells with a range of 
avidities for the closely-related, heterologous DENV serotypes.  Upon secondary 
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heterologous DENV infection, serotype-cross-reactive memory T cells are activated and 
mount an effector response.  This response, however, is inadequate as it is dominated by 
presumably low avidity, serotype-cross-reactive T cells instead of high avidity serotype-
specific T cells.  An inadequate T cell response would result in an altered cytokine profile 
(e.g. unusually high TNFα production) that could contribute to dengue pathology. 
To test the role of T cells in DENV infection, analysis of blood samples from 
DENV-immune individuals detected circulating T cells which proliferated and produced 
cytokines upon in vitro DENV stimulation (Kurane, et al., 1989a).  Importantly, these 
cells could also lyse target cells presenting DENV antigen from homologous or 
heterologous serotypes; this was seen at the bulk population and T cell clonal level, 
revealing the serotype-cross-reactive potential of both CD4+ and CD8+ T cells 
(Bukowski, et al., 1989; Kurane, et al., 1989b; Green, et al., 1993; Dharakul, et al., 1994; 
Livingston, et al., 1995; Gagnon, et al., 1996).  These studies used peripheral blood 
mononuclear cells (PBMC) from subjects vaccinated with experimental live-attenuated 
DENV strains and noted that the response to stimulation with whole viral antigens of the 
homologous DENV serotype (i.e. the serotype with which the individual was immunized) 
was generally greater than the response to stimulation with heterologous serotypes.  One 
report analyzed PBMC from subjects with naturally-acquired primary DENV infections 
and found that DENV-2 immune T cells responded best to DENV-2 with some cross-
reactivity toward the other serotypes, whereas DENV-1 immune T cells proliferated 
equally well to DENV-1 and DENV-2 with some response toward DENV-3 and -4 
(Sierra, et al., 2002).  This study highlighted the influence of distinct DENV serotypes on 
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the response of T cells and suggested that there may also be differences in the T cell 
response generated by subjects naturally exposed to DENV versus those exposed through 
vaccination.   
Advancing technology allowed for the identification of multiple T cell epitopes in 
DENV (Livingston, et al., 1995; Gagnon, et al., 1996; Mathew, et al., 1996; Mathew, et 
al., 1998; Zivny, et al., 1999; Appanna, et al., 2007).  Studies on PBMC from individuals 
immunized with experimental DENV vaccines or patients with natural secondary 
infection indicated that cytotoxic T lymphocyte responses were mainly directed against 
the more conserved non-structural viral proteins, in particular NS3 and NS1-2a, although 
some responses were detected against E and preM (Mathew, et al., 1996; Mathew, et al., 
1998).  A more recent study assessing responses to the entire DENV genome in PBMC 
from subjects with naturally-acquired secondary infections confirmed that the majority of 
T cell responses were directed at NS3 (Duangchinda, et al., 2010).  Epitope identification 
enabled investigators to determine the breadth and magnitude of particular T cell subsets 
that contribute to the global anti-DENV T cell response.  Functional analyses of epitope-
specific T cells confirmed the presence of serotype-specific and serotype-cross-reactive 
subsets (Livingston, et al., 1995; Gagnon, et al., 1996; Zivny, et al., 1999), and one study 
suggested that the TCRs for these different epitope-specific T cell subsets may use 
distinct variable region gene segments (Livingston, et al., 1995).   
Supporting a role for altered cytokine responses in dengue pathology, a study 
using PBMC obtained after naturally-acquired primary DENV infections demonstrated 
that the production of TNFα after in vitro stimulation only occurred in those individuals 
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who were subsequently hospitalized during a secondary DENV infection (Mangada, et 
al., 2002).  On the other hand, individuals with broadly serotype-cross-reactive IFNγ 
responses tended to experience sub-clinical secondary infections.  Whether such an 
alteration in effector response could occur due to the stimulation of epitope-specific T 
cells by an epitope variant from a heterologous serotype (i.e. naturally-occurring APL) 
prompted experiments that evaluated multiple effector functions in response to epitope 
variants.  The ratio of IFNγ/TNFα production by CD4+ T cells in subjects that received a 
live-attenuated DENV vaccine favored TNFα production when stimulated by 
heterologous serotypes compared to stimulation with the homologous serotype (Mangada 
and Rothman, 2005).  The hierarchy of T cell effector responses (proliferation, cytokine 
production, degranulation and/or cytotoxicity) directed toward a particular epitope was 
found to differ depending on the individual, the serotype from which the epitope 
sequence was derived, and the epitope itself (Zivny, et al., 1999; Bashyam, et al., 2006; 
Mongkolsapaya, et al., 2006; Imrie, et al., 2007).  These data supported studies assessing 
ex vivo effector responses of epitope-specific T cells in early convalescence, which 
demonstrated higher cytokine production than degranulation in serotype-cross-reactive 
versus serotype-specific T cells (Mongkolsapaya, et al., 2006) and in T cells from 
subjects with DHF versus DF (Duangchinda, et al., 2010).  A similar pattern was 
observed in virus-stimulated PBMC from subjects who had primary DENV infection 
several years prior, which showed greater induction of regulatory cytokines (TGFβ and 
IL-10) after homologous stimulation versus an increased pro-inflammatory response 
(TNFα and IFNγ) after heterologous stimulation (Sierra, et al., 2010).  Such analyses 
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indicate that DENV-specific T cells exhibit a balanced response to re-challenge with the 
same serotype, but a skewed response to heterologous DENV infection, favoring 
excessive pro-inflammatory cytokine production, and may be a major source of 
circulating TNFα, or other supposed detrimental responses, in DHF.   
The development of soluble peptide-MHC tetrameric complexes made possible 
the detection of epitope-specific T cells without reliance on a functional readout (Altman, 
et al., 1996).  As functional responses of DENV-specific T cells change according to the 
stimulus, staining with pMHC tetramers specific for epitopes encoded by the different 
DENV serotypes enabled assessment of serotype-cross-reactivity unrelated to function.  
Staining DENV-immune PBMC with multiple pMHC tetramer variants simultaneously 
demonstrated that, in some subjects with secondary infection, the majority of epitope-
specific T cells bound tetramers containing peptides from DENV serotypes other than the 
currently-infecting serotype (Mongkolsapaya, et al., 2003; Mongkolsapaya, et al., 2006; 
Dong, et al., 2007).  These results were interpreted to indicate that the T cells which 
bound to heterologous pMHC tetramer variants were reactivated memory T cells 
generated during a previous DENV infection.  This, together with the finding that 
DENV-specific T cell responses can differ according to the serotype used for stimulation, 
fit with the model of original antigenic sin.   
To have a better understanding of how T cell responses relate to the onset of 
clinical symptoms, recent studies have used pMHC tetramer technology to investigate the 
kinetics of expansion and activation of DENV-specific T cells during acute infection and 
convalescence.  Mongkolsapaya, et al. reported that the frequency of T cells specific for 
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an immunodominant HLA-A*1101-restricted epitope on the NS3 protein (NS3133-142) 
peaked two weeks after the conclusion of fever (defervescence) in Thai children with 
secondary DENV infections (Mongkolsapaya, et al., 2003).  Similar findings were later 
reported by this group for a different DENV epitope as well (Mongkolsapaya, et al., 
2006).  The peak frequency of A11-NS3133-specific T cells occurred earlier (within days 
of defervescence) in a study of Vietnamese infants (Chau, et al., 2008), raising the 
possibility of a difference in the kinetics of this response between different age groups or 
between primary and secondary infections.  Differences in timing of sample collection 
might also obscure the time at which true T cell frequencies peak.  Regardless, some 
groups noted an association between the magnitude of epitope-specific T cell responses 
and the severity of dengue disease (Zivna, et al., 2002; Mongkolsapaya, et al., 2003; 
Mongkolsapaya, et al., 2006), while others did not (Simmons, et al., 2005b; Chau, et al., 
2008; Dung, et al., 2010).  One study reported that neither epitope-specific nor total 
activated CD8+ T cells were detected at all prior to the onset of clinical features of severe 
dengue disease (Dung, et al., 2010), which led them to question the role of T cells in the 
induction of DHF.  Studies with samples from more time points and greater numbers of 
subjects, including those differentiated by serology (i.e. primary versus secondary 
infection) and serotype of infection, will help to clarify any correlation of T cell 
responses with disease outcome.   
While evidence points to the involvement of T cells in DENV infection, their role 
in disease pathogenesis remains unclear and many questions linger.  Few studies have 
compared T cell responses in natural primary and secondary infections; only recently 
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Duangchinda, et al. distinguished between these two groups and found higher cytokine 
responses in secondary infection (Duangchinda, et al., 2010).  Studies have yet to address 
whether T cells are more activated or have a different phenotype in primary versus 
secondary infection.  In addition, no study has evaluated T cell serotype-cross-reactivity 
in primary infection to determine whether heterologous tetramer binding is the result of 
original antigenic sin.  Furthermore, in-depth characterization of DENV-specific T cell 
lines has been largely limited to those isolated from vaccine donors or subjects with 
secondary infections.  T cells from subjects with natural primary infection, however, are 
those in position to respond in secondary heterologous infection (a risk factor for severe 
disease).  Therefore, detailed analysis of these cells will help us to understand their 
potential role in dengue disease. 
 
N. Thesis objectives 
 Due to their low threshold for activation and rapid response time relative to naïve 
T cells, memory CD8+ T cells generated by a primary DENV infection are primed to 
respond during a subsequent DENV infection.  This thesis sought to characterize this 
‘first generation’ DENV-specific T cell response to natural infection and to reveal its 
capacity for serotype-cross-reactivity upon subsequent DENV exposure.  This work helps 
to identify the differences in the phenotype and function of T cells generated in primary 
infection to those generated in secondary infection and provides insight into the 
mechanism(s) of T cell involvement in the development of severe dengue disease. 
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We hypothesized that: 
a) DENV-specific memory T cells generated after primary DENV infection 
differ from those detected after secondary infection by way of frequency, 
extent of cross-reactivity, and phenotype (e.g. activation, effector/memory) 
b) serotype-cross-reactive memory T cells detected after primary infection 
respond differently to heterologous compared to homologous stimulation 
(e.g. cytokine responses versus cytotoxicity, qualitatively different TCR-
mediated signaling events) 
c) qualitatively distinct T cell subsets contribute to an immunopathological 
outcome  
 
This work is presented in two parts: 
CHAPTER III: Striking Cross-reactivity and Expansion of Dengue Virus-specific  
   CD8+ T cells During Acute Primary and Secondary Infections in  
   Humans  
Questions:  
• Are T cell responses to primary DENV infection predominantly serotype-specific, in 
contrast to secondary DENV infection? 
• Do T cell responses to different epitopes follow the same kinetics within individual 
subjects? 
• How do the characteristics of the DENV-specific T cell response (e.g. magnitude, 
cross-reactivity, or activation) correlate with disease severity?  
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Approach: 
• Stain PBMC from DENV-infected subjects (obtained throughout acute infection 
and convalescence) with multiple DENV serotype-specific epitope variants 
together with a panel of activation and phenotypic markers 
• Perform ex vivo stimulation of DENV-immune PBMC with epitope variants to 
measure degranulation and cytokine production by T cells 
 
CHAPTER IV: Memory CD8+ T cells from Subjects with Naturally-acquired  
   Primary Dengue Virus Infection are Functionally Cross-reactive  
Questions: 
• What types of T cells comprise the A11-NS3133 epitope-specific T cell repertoire? 
• Do different epitope variants induce variable effector responses from T cell 
clones? 
• Do signaling events downstream of peptide stimulation correlate with variable 
effector responses? 
Approach: 
• Stimulate PBMC with A11-NS3133 peptide variants and isolate epitope-specific 
CD8+ T cell clones 
• Assess serotype-cross-reactivity by pMHC tetramer binding, cytotoxicity, and 
cytokine responses 
• Compare T cell signaling and effector function of T cells after stimulation with 
the different serotype-specific epitope variants 
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CHAPTER II 
MATERIALS AND METHODS 
 
A. Patient recruitment and collection of blood samples 
 Blood samples were collected from subjects enrolled in an ongoing clinical study 
of acute DENV infections in Thailand; the study design has been reported in detail 
elsewhere (Kalayanarooj, et al., 1997; Vaughn, et al., 1997).  Briefly, the subjects 
enrolled in the study were Thai children 6 months to 14 years of age with acute febrile 
illnesses.  Serology and virus isolation from acute phase plasma were used to confirm 
acute DENV infections, and primary and secondary infections were distinguished based 
on serologic responses (primary infection = IgM:IgG ratio ≥1.8:1 and hemagglutination-
inhibition [HAI] antibody titer ≤1:1280; secondary infection = IgM:IgG ratio <1.8:1 and 
HAI antibody titer >1:1280).  The serotype of infection was determined by ELISA, using 
monoclonal antibodies specific for E protein from the different DENV serotypes and 
supernatants from C6/36 cells infected with virus isolated from acute patient samples 
(Vaughn, et al., 1997).  Blood samples were obtained daily during acute illness, once in 
early convalescence (approximately 10 days after enrollment, corresponding to 5-7 days 
after defervescence), and at 6-12 month intervals during late convalescence (6 months to 
3 years after study entry).  Time points are reported relative to the day of defervescence 
(i.e. the day at which fever dissipated and the patient subsequently maintained a 
temperature below 38°C), which was termed fever day 0 (d0).  Fever days -1, -2, etc. 
occurred before defervescence, and day +1, etc. occurred after defervescence.  Written 
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informed consent was obtained from each subject and/or his/her parent or guardian and 
the study design was approved by the Institutional Review Boards of the Thai Ministry of 
Public Health, the Office of the U.S. Army General and the University of Massachusetts 
Medical School.  PBMC were isolated by density gradient centrifugation, cryopreserved, 
and stored in liquid nitrogen.  Frozen PBMC were shipped on dry ice to the University of 
Massachusetts Medical School for analysis.  HLA typing was performed on blood 
obtained 6 months or more after acute illness at the University of Massachusetts Medical 
School or the Department of Transfusion Medicine, Siriraj Hospital, as previously 
described (Mathew, et al., 1998; Stephens, et al., 2002).  We also used blood samples 
from a U.S. volunteer obtained 8 months after vaccination with an experimental live-
attenuated monovalent DENV vaccine (DEN-1 45AZ5), as previously described (Green, 
et al., 1993).   
 
B. Peptides and generation of peptide-MHC tetramers 
 Peptides specific for three variants of the HLA-A*1101-restricted DENV NS3133-
142 epitope (Mongkolsapaya, et al., 2003) were synthesized at >90% purity from 
AnaSpec, Inc. (San Jose, CA, USA).  Peptide-MHC (pMHC) tetramers of these epitope 
variants were generated at the University of Massachusetts Medical School Tetramer 
Core as previously described (Luzuriaga, et al., 2000).  Biotinylated pMHC monomers 
were mixed with the respective avidin-conjugated fluorochrome at a molar ratio of 4:1 to 
form tetramers.  Multimers were also made (mixed at molar ratios of 25:1 and 50:1, 
respectively) for the HLA-A*0201-restricted M158-66 influenza epitope 
Epitope HLArestriction Serotype Sequence Designation
a
DENV NS3133-142b A*1101 DENV-1 GTSGSPIVNR pD1
DENV-2 GTSGSPIVDR pD2
DENV-3, -4 GTSGSPIINR pD3/4
DENV NS3222-231c B*07 DENV-2, -3, -4 APTRVVAAEM B7-DENV
Influenza M158-66d A*0201 n/a GILGFVFTL A2-Flu
Table 2.1. Summary of epitope sequence information.
aAs used in this paper
bIdentified by Mongkolsapaya, et al., 2003
cIdentified by Mathew, et al., 1998
dIdentified by Bednarek, et al., 1991 and Morrison, et al., 1992
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A11+DENV+ PBMC
A11+DENV– PBMC
pD1 pD2
C
D
8
pD3/4
Epitope-specific T cell line
A11–DENV+ PBMC
FIGURE 2.1. Specificity of pMHC tetramers generated for this study.
(A) Peptide-MHC tetramers specific for each of three A11-NS3133 DENV epitope variants were 
generated.  Tetramer specificity was verified by staining PBMC from HLA-A*1101+ DENV-naïve, 
HLA-A*1101- DENV-immune, and HLA-A*1101+ DENV-immune subjects as well as an epitope-
specific T cell line.  Cells were gated on live, CD3+ singlet lymphocytes.  (B) A B7-NS3222 DENV 
epitope-specific T cell line was established previously (Zivna, et al., 2002) and was spiked into a 
non-specific T cell line to ensure pMHC tetramer specificity.  (C) An A2-M158 Flu epitope-specific 
T cell clone was established previously (Jameson, et al., 1998) and was spiked into a non-specific 
T cell line to ensure pMHC tetramer specificity.  Cells shown in (B) and (C) were gated on live, 
CD3+CD8+ singlet lymphocytes.
A A11-NS3133 DENV epitope-specific tetramers B
C
B7-NS3222 DENV epitope-specific tetramer
A2-M158 Flu epitope-specific tetramer
No tetramer + tetramer
No tetramer + tetramer
A2-Flu
C
D
8
C
D
8
B7-DENV
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(Bednarek, et al., 1991; Morrison, et al., 1992) and the HLA-B*07-restricted DENV 
NS3222-231 epitope (Mathew, et al., 1998).  The different pMHC complexes were 
conjugated to distinct fluorochromes to allow for staining with multiple epitopes/variants 
simultaneously (APC-A11-NS3133-pD1, PE-Cy7-A11-NS3133-pD2, PE-A11-NS3133-
pD3/4, Qdot-605-A2-Flu, Qdot-605-B7-NS3222).  Peptide sequences are shown in Table 
2.1; the specificity of each pMHC multimer (from here on all are referred to as tetramers, 
for simplicity) was confirmed as shown in Figure 2.1. 
 
C. Tetramer staining and phenotypic characterization of PBMC  
 Cryopreserved PBMC were thawed and washed in RPMI before resting in 
RPMI/10% FBS at 37°C for approximately 2 hours.  Cells were washed in PBS and 
stained with the dead cell marker LIVE/DEAD Aqua (Molecular Probes, Invitrogen 
Corp., Carlsbad, CA, USA) according to the manufacturer’s instructions.  Cells were then 
washed and incubated with 0.5-2µL pMHC tetramer for 20 minutes at 4°C.  Monoclonal 
antibodies (mAbs) specific for CD3 (clone UCHT1, Alexa Fluor 700 or clone SK7, 
PerCP-Cy5.5; BD Biosciences, San Jose, CA, USA), CD8 (clone SK1, PerCP-Cy5.5 
from BD Biosciences or clone 3B5, Qdot-655 from Invitrogen Corp. or clone RAP-T8, 
Alexa Fluor 700 from BD Biosciences), CD45RA (clone HI100, FITC; BD Biosciences), 
CCR7 (clone 3D12, APC-eFluor 780; eBioscience, San Diego, CA, USA), CD127 (clone 
eBioRDR5, Pacific Blue from eBioscience), CD38 (clone HIT2 conjugated to Qdot-655 
from Invitrogen Corp. or to PerCP-Cy5.5 from BD Biosciences) and/or CD69 (clone 
FN50, APC-Cy7; BD Biosciences) were then added to the cells and incubated at 4°C for  
Fluorochrome
/channel Panel 1A Panel 1B Panel 2 Panel 3
APC pD1 tetramer pD1 tetramer pD1 tetramer pD1 tetramer
PE-Cy7 pD2 tetramer pD2 tetramer pD2 tetramer --
PE pD3/4 tetramer pD3/4 tetramer pD3/4 tetramer --
LIVE/DEAD Aqua Dead cells Dead cells Dead cells Dead cells
AlexaFluor 700 CD3 CD3 Granzyme B CD8
PerCP-Cy5.5 CD8 CD38 CD3 CD38
FITC CD45RA CD45RA Ki-67 CD45RA
APC-eFluor 780 CCR7 CCR7 CD69a CCR7
Pacific Blue CD127 CD127 Bcl-2b CD127
Qdot-655 CD38 CD8 CD8 pMHC multimerc
Table 2.2. List of antibodies/markers used in 10 (or 8)-color staining panels for ex vivo 
analysis of DENV-immune PBMC.
aThe antibody for CD69 was conjugated to APC-Cy7
bThe antibody for Bcl-2 was conjugated to AlexaFluor 405
cThe B7-NS3222 DENV and A2-M158 Flu pMHC multimers were conjugated to Qdot-605
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an additional 30 minutes.  Cells were washed and either fixed with BD Stabilizing 
Fixative (BD Biosciences) or permeabilized with BD Cytofix/Cytoperm (BD 
Biosciences) for 20 minutes at 4°C.  After permeabilization, cells were washed and 
incubated with mAbs against Ki-67 (sc-23900, FITC; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), Bcl-2 (sc-7382, Alexa Fluor 405; Santa Cruz Biotechnology), and 
granzyme B (clone GB11, Alexa Fluor 700; BD Biosciences) for 30 minutes at 4°C.  
Finally, cells were washed and fixed as above.  Data were collected on a BD FACSAria 
and analyzed using FlowJo version 7.5.5.  Table 2.2 lists the antibodies/markers used for 
each staining panel. 
 
D. Bulk culture and cloning of PBMC and maintenance of T cell lines 
 Cryopreserved PBMC were thawed and stimulated in vitro with 10µg/mL peptide 
in complete RPMI 1640 medium supplemented with 10% heat-inactivated FBS and 
5ng/mL IL-7.  Cells were fed with RPMI/10% FBS medium containing 50U/mL IL-2 on 
day 3 and every 2-3 days thereafter.  After 2 to 3 weeks, T cells were positively selected 
using the tetramer specific for the DENV-1 variant of the A11-NS3133 epitope together 
with MACS α-allophycocyanin (APC) microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany).  T cell lines were then generated by limiting dilution (3 or 10 cells/well) and 
maintained by biweekly re-stimulation with α-CD3, allogeneic irradiated PBMC, and 
50U/mL IL-2. 
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E. Tetramer staining of T cell lines 
 Approximately 0.1–1x106 cells were stained with a dead cell marker 
(LIVE/DEAD Aqua; Molecular Probes, Invitrogen Corp.) according to the 
manufacturer’s instructions.  After washing, cells were stained with 0.5-2µL of each 
tetramer for 20 minutes at 4°C before addition of mAb directed at the surface markers 
CD3 (clone UCHT1, Alexa Fluor 700; BD Biosciences), CD8 (clone SK1, PerCP-Cy5.5; 
BD Biosciences), and CD4 (clone OKT4, Pacific Blue; eBioscience) for 30 minutes at 
4°C.  Cells were washed and placed in BD Cytofix or BD Stabilizing Fixative until 
analysis.  Data were collected on a BD FACSAria and analyzed using FlowJo version 
7.2.2 or 7.2.4. 
 
F. Cytotoxicity assay 
 Cytotoxicity was assessed as previously described (Mathew, et al., 1998).  
Briefly, HLA-A*1101+ B-lymphoblastoid cell line (BLCL) targets were labeled with 51Cr 
for 1 hour, washed, and pulsed with 0.01 – 10µg/mL of the indicated peptide.  Target 
cells were cultured with T cells at an effector-to-target ratio of 10:1.  Wells containing 
targets with no effectors were used to determine background (‘minimum’) 51Cr release; 
wells containing targets with no effectors but with detergent (to lyse the target cells) were 
used to determine ‘maximum’ 51Cr release.  After 4 hours, supernatants were harvested 
and 51Cr content was measured in a gamma counter.  Percent specific lysis was calculated 
by the following formula: % lysis = (experimental 51Cr release – minimum 51Cr release) / 
(maximum 51Cr release – minimum 51Cr release) x 100. 
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G. Intracellular cytokine staining assay 
 PBMC or T cells (2x105) and HLA-A*1101+ BLCL (2x104) were cultured with 
0.01 – 10µg/mL peptide, anti-CD107a (clone H4A3, FITC; BD Biosciences), brefeldin A 
and monensin (BD GolgiPlug and BD GolgiStop; BD Biosciences) for 6 hours.  Cells 
were washed and stained with the viability marker LIVE/DEAD Aqua before subsequent 
staining with mAbs specific for CD3 (clone SK7, APC-H7; BD Biosciences), CD14 
(clone SJ25C1, PE-Cy7; BD Biosciences), CD19 (clone M5E2, PE-Cy7; BD 
Biosciences), CD8 (clone SK1, PerCP-Cy5.5; BD Biosciences), and CD4 (clone OKT4, 
Pacific Blue; eBioscience) at 4°C for 30 minutes.  After washing, the cells were fixed and 
permeabilized (BD Cytofix/Cytoperm; BD Biosciences) before staining with mAbs 
specific for IFNγ (clone B27, Alexa Fluor 700; BD Biosciences), MIP-1β (clone D21-
1351, PE; BD Biosciences), and TNFα (clone Mab11, APC; BD Biosciences).  Cells 
were washed again and placed in fixative until data collection. 
 
H. Drug inhibition studies 
 Intracellular cytokine staining assays were performed as above but included pre-
treatment of T cells with cyclosporine A (CSA).  Prior to stimulation, T cells (together 
with BLCL) were incubated with 0.01-1µM CSA for 30 minutes at 37°C.  Cells were 
then washed and incubated in the presence of peptide, anti-CD107a and protein transport 
inhibitors as above. 
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I. Phosphoflow signaling assay 
 T cell receptor-induced signaling events were analyzed by flow cytometry as 
described (Perez, et al., 2005) and modifying the methods detailed by BD Biosciences 
(Techniques for Phospho Protein Analysis Application Handbook, First edition, 
<www.bdbiosciences.com>).  Briefly, 4x105 HLA-A*1101+ BLCL and 2x105 T cells 
were pulsed with 0.01 – 10µg/mL peptide for 30 minutes on ice.  Cells were then washed 
and placed in 1% FBS in PBS for 3 or 10 minutes in a 37ºC water bath.  Cells were 
immediately fixed (Phosflow Fix Buffer I; BD Biosciences), washed, and then 
permeabilized (Phosflow Perm Buffer III; BD Biosciences) on ice for 30 minutes.  After 
washing, cells were blocked with mouse IgG for 10 minutes prior to addition of mAbs 
specific for CD3 (clone SK7, PerCP-Cy5.5; BD Biosciences), CD4 (clone RPA-T4, 
APC; BD Biosciences), CD8 (clone RPA-T8, PE; BD Biosciences), and phosphorylated 
CD3ζ (clone K25-407.69, Alexa Fluor 488; BD Biosciences) or phosphorylated ERK1/2 
(clone 20A, Alexa Fluor 488; BD Biosciences) for an additional 30 minutes at room 
temperature.  Cells were washed and placed in fixative until data collection. 
 
J. Vβ analysis 
 Flow cytometric analysis (surface staining) of Vβ usage for epitope-specific TCRs 
was performed using the IOTest Beta Mark TCR Vβ Repertoire kit (Beckman Coulter, 
Brea, CA, USA).  Briefly, the protocol was the same as that detailed above for tetramer 
staining of T cell lines but included the addition of 20µL of the respective Vβ staining 
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vial along with the mAbs against CD3, CD8 and CD4 before incubating at 4°C for 30 
minutes. 
 
K. Peptide-MHC binding prediction analysis 
MHC class I binding prediction scores were calculated for the three A11-NS3133 
epitope variants used in this study according to three prediction models provided by the 
Immune Epitope Database and Analysis Resource website 
(<http://tools.immuneepitope.org/main/html/tcell_tools.html>).   
 
L. CD137 expression analysis 
Approximately 2x105 T cells were cultured together with 2x104 HLA-A*1101+ 
BLCL and 10µg/mL peptide in RPMI/10% FBS at 37°C for 0-24 hours.  At T-30min, 
cells were washed in PBS and stained with LIVE/DEAD Aqua as above, then fixed 
(Phosflow Fix Buffer I; BD Biosciences) and placed at 4°C until all time points were 
collected.  At the end of the time course, all of the cells were washed and stained with 
mAbs against CD3 (clone UCHT1, V450; BD Biosciences), CD8 (clone RPA-T8, Alexa 
Fluor 700; BD Biosciences), CD4 (clone RPA-T4, APC; BD Biosciences), and CD137 
(clone 4B4-1, PE; BD Biosciences) for 30 minutes at room temperature.  Finally, cells 
were washed and placed in fixative until data collection. 
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M. Statistical analysis 
 For variables with a normal distribution, t-tests were used to compare continuous 
outcomes at a single time point between two groups and random intercept models were 
used to make comparisons between multiple groups across time points with the 
assumption that each individual within a group follows the same slope.  For these models, 
missing values in the CD38 and CD45RA data sets were imputed with the means of all 
donors at each time point.  For variables that were not normally distributed, the Mann-
Whitney rank sum test was used to make comparisons between two groups and 
Friedman’s test was used to make comparisons between three or more groups.  
Correlations between skewed variables were determined using Spearman's rank 
correlation.  Fischer’s exact test was used to compare categorical data.  P values of ≤0.05 
were considered significant; p values of ≤0.1 but >0.05 were considered indicative of 
non-significant trends.  All statistical analyses were performed with help from James 
Potts, using Stata Intercooled version 9 (Stata Corporation, College Station, TX, USA) 
and GraphPad Prism (La Jolla, CA, USA) software packages. 
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CHAPTER III 
STRIKING CROSS-REACTIVITY AND EXPANSION OF DENGUE VIRUS-
SPECIFIC CD8+ T CELLS DURING ACUTE PRIMARY AND SECONDARY 
INFECTIONS IN HUMANS 
 
 Various studies have explored the immunopathogenic role of cross-reactive 
memory T and B cells in DENV infection utilizing blood samples from DENV-infected 
human subjects.  A high percentage of DENV-specific T cells recognize multiple DENV 
serotypes (Bashyam, et al., 2006; Dong, et al., 2007; Imrie, et al., 2007; Mangada and 
Rothman, 2005; Mongkolsapaya, et al., 2003; Mongkolsapaya, et al., 2006; Moran, et al., 
2008; Sierra, et al., 2002; Zivny, et al., 1999), and patients with more severe disease 
(DHF) have been shown to have higher overall levels of T cell activation in vivo than 
patients with milder disease (DF) (Green, et al., 1999a; Green, et al., 1999b; Green, et al., 
1999c; Kurane, et al., 1991; Libraty, et al., 2002a; Perez, et al., 2004).  A few studies 
have reported a higher frequency of DENV epitope-specific T cells in patients with DHF 
(Mongkolsapaya, et al., 2003; Mongkolsapaya, et al., 2006; Zivna, et al., 2002), but other 
studies have found no association and have questioned the timing of T cell activation 
(Chau, et al., 2008; Dung, et al., 2010).  Comparison of these divergent studies is 
complicated by differences in methods, study populations, infecting viruses and the T cell 
epitopes studied.  However, none of the previous reports have incorporated a comparison 
of responses to multiple epitopes in cohorts with naturally-acquired primary and 
secondary infection in association with data on outcome of infection.   
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We therefore took advantage of a long-standing collaboration between our 
laboratory, the Queen Sirikit National Institute of Child Health, and the Armed Forces 
Research Institute of Medical Sciences, both of which are in Thailand, which established 
a longitudinal study to follow children with naturally-acquired primary and secondary 
DENV infections (Kalayanarooj, et al., 1997; Vaughn, et al., 1997).  Blood samples were 
obtained from patients throughout acute infection and up to three years post-
defervescence.  We selected subjects who were positive for HLA-A11 and/or HLA-B7 to 
analyze the frequency, serotype-cross-reactivity and phenotype of T cells specific for two 
previously identified immunodominant DENV epitopes. 
 
A. T cells specific for an immunodominant HLA-A11-restricted DENV epitope 
expand during acute infection  
To compare the magnitude and kinetics of epitope-specific CD8+ T cells in 
patients with primary or secondary DENV infection, we initially focused on subjects with 
HLA-A11, an allele common in the Thai population (Chandanayingyong, et al., 1997), 
for which an immunodominant epitope (NS3133-142) had been previously reported 
(Mongkolsapaya, et al., 2003).  Our study cohort included 44 HLA-A*1101+ Thai 
children including 17 with primary DENV infection and 27 with secondary DENV 
infection (Table 3.1).  The cohort included cases of infection with all four DENV 
serotypes; however, there was only 1 subject with DENV-4 infection (a secondary 
infection) and only 7 with DENV-2 infection (5 of which were secondary infections).  To 
distinguish serotype-cross-reactive T cells, we generated three A11-NS3133 pMHC  
Table 3.1. List of HLA-A*1101+ and HLA-B*07+ subjects and clinical information.
Subject Serologya Serotypeb Diagnosisc MHC Class I HaplotypeA             B             C
Peak Tet+
Frequencyd
(%)
PEIe
Change in 
Hematocritf
(%)
Max. ASTg
(IU/L)
Min. 
Plateleth
(cells/mm3)
C94127 1º DENV-1 DF 11,33 44,61 7 0.19 0 17.65 49 104
C95017 1º DENV-1 DF 11,24 38,75 7,1 0.18 0 17.14 32 157
C95031 1º DENV-1 DF 11,33 58,60 3,7 ndi 0 13.51 172 146
C95039 1º DENV-1 DF 1,11 56,57 6,7 19.13 0 40.74 146 240
C96040 1º DENV-1 DF 11 62 6 0.37 0 18.92 41 250
C00015 1º DENV-1 DF 11,24 7,60 nd nd 0 15.79 55 114
C96041 1º DENV-1 DHF II 11 51,62 4 0.52 20 59.38 1253 17
C00002 1º DENV-2 DF 2,11 13,61 nd 0.68 0 11.43 38 243
C01030 1º DENV-2 DF 11,33 13,58 nd 0.18 0 14.29 37 238
C95059 1º DENV-3 DF 11,24 27,54 1,7 0.91 0 11.11 41 179
C96062 1º DENV-3 DF 2,11 62,46 1,6 0.35 0 22.06 56 142
C96106 1º DENV-3 DF 11,33 7,51 nd 0.74 naj na na na
C97035 1º DENV-3 DF 11,24 39,51 nd 1.22 0 42.42 36 80
C99091 1º DENV-3 DF 2,11 18,62 nd 1.29 0 25 322 91
C95054 1º DENV-3 DHF I 2,11 13,38 7 1.34 2.12 15.63 51 152
C95089 1º DENV-3 DHF II 11,24 18,52 7,1 2.27 2.88 20 58 173
C96025 1º DENV-3 DHF II 11,26 51,60 3 12.77 na na na na
C95090 2º DENV-1 DF 2,11 46 1 1.56 0 17.65 33 157
C96089 2º DENV-1 DF 11,24 7,60 7 2.32 0 13.16 55 174
C97025 2º DENV-1 DF 11 70,75 1 17.32 0 17.65 109 71
C97047 2º DENV-1 DF 11 46 nd 0.67 0 10.81 141 76
C97141 2º DENV-1 DF 2,11 61,75 nd nd 0 18.42 56 95
C96069 2º DENV-1 DHF II 11,24 18,55 1,7 0.25 25 32.35 160 11
C97024 2º DENV-1 DHF III 11 7,38 nd 6.95 16.66 21.21 347 49
Continued on next page
55
Subject Serologya Serotypeb Diagnosisc MHC Class I HaplotypeA             B             C
Peak Tet+
Frequencyd
(%)
PEIe
Change in 
Hematocritf
(%)
Max. ASTg
(IU/L)
Min. 
Plateleth
(cells/mm3)
K95011 2º DENV-1 DHF I 11 13 3 0.15 21.05 34.55 176 45
C01017 2º DENV-1 DHF II 11,29 7,75 nd 0.57 4.67 17.65 109 46
C96088 2º DENV-1 DHF II 2,11 38,55 1,7 0.79 21.69 20.51 623 20
C96094 2º DENV-1 DHF II 11,24 54,63 1,7 0.64 12.26 25 91 93
C01010 2º DENV-2 DF 11,11 7,27 nd 0.83 0 8.57 363 176
C02066 2º DENV-2 DF 11,24 13,27 nd 1.09 2.15 14.29 44 146
C00001 2º DENV-2 DHF II 11,24 48,75 nd 0.62 19.98 17.95 56 29
C01078 2º DENV-2 DHF II 1,11 37,58 nd nd nd 21.62 21 82
C02063 2º DENV-2 DHF III 11,24 35,51 nd nd 61.38 27.5 627 36
C95075 2º DENV-3 DF 11,30 13 3 0.57 na na na na
C96016 2º DENV-3 DF 11,30 13,46 1,6 2.15 0 13.51 81 93
C99014 2º DENV-3 DF 11,33 7,44 nd nd 0 16.22 131 72
C00026 2º DENV-3 DF 11,33 7,60 nd 0.51 0 18.42 97 70
C96045 2º DENV-3 DHF II 11,24 13,62 3,6 2.19 24.56 32.5 187 7
C97019 2º DENV-3 DHF III 2,11 35,51 4 0.14 37.35 27.78 709 22
C97027 2º DENV-3 DHF II 11,26 60 nd 0.41 2.08 19.44 138 64
C97036 2º DENV-3 DHF II 11,33 7,75 6 nd 1.03 72.41 438 46
C97044 2º DENV-3 DHF II 2,11 13,75 nd 0.45 9.3 16.67 107 43
K95005 2º DENV-3 DHF I 2,11 35,38 4,7 2.30 3.96 9.59 95 164
C00025 2º DENV-4 DF 11 75 nd 1.55 0 16.22 69 57
Subjects on whom only B7-NS3222 tetramer analysis was done:
C95029 1º DENV-3 DF 24,34 7,75 1,6 0.23 0 40.63 50 186
C95098 2º DENV-1 DHF II 29 7,61 3 7.35 0 27.03 301 48
Table 3.1. List of HLA-A*1101+ and HLA-B*07+ subjects and clinical information. (cont’d)
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Subject Serologya Serotypeb Diagnosisc MHC Class I HaplotypeA             B             C
Peak Tet+
Frequencyd
(%)
PEIe
Change in 
Hematocritf
(%)
Max. ASTg
(IU/L)
Min. 
Plateleth
(cells/mm3)
K94024 2º DENV-2 DHF III 2,24 7,46 1,7 8.12 16.26 43.66 130 28
C94115 2º DENV-3 DF 2,29 7,60 3 1.10 0 5.71 44 149
K97093 2º DENV-3 DF 24,33 7,44 7,7 1.17 0 19.44 180 70
C97014 2º DENV-3 DHF III 3,11 7,13 4,6 0.33 27.84 48.57 177 40
C94094 2º DENV-4 DHF I 2,11 7,13 3,7 7.01 2.5 10.26 94 140
C94132 2º DENV-4 DHF II 11,29 7,75 8 1.14 3.26 2.7 101 200
Table 3.1. List of HLA-A*1101+ and HLA-B*07+ subjects and clinical information. (cont’d)
aPrimary (1º) or secondary (2º) infection
bOf current infection
cAccording to WHO guidelines; DF = dengue fever, DHF I-IV = dengue hemorrhagic fever, grades I-IV
dA11-NS3133 or B7-NS3222 tetramer-positive T cells detected <1 year post-defervescence
ePEI = pleural effusion index
fAs calculated using measurements taken over the course of hospitalization: max-min/min X 100
gAST = aspartate aminotransferase; IU/L=international units per liter
hAs measured throughout hospitalization; values shown are divided by 1000
ind = not determined
jna = not available
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tetramers, each containing a peptide variant corresponding to a different DENV serotype.  
The epitope sequences for DENV-3 and DENV-4 are identical (designated as pD3/4) and 
differ, as does the DENV-2 sequence (pD2), by a single amino acid from the DENV-1 
sequence (pD1; refer to Table 2.1).  
Figure 3.1A details the gating strategy employed to identify A11-NS3133 tetramer-
positive T cells.  Each experiment included PBMC from a healthy DENV-naïve negative 
control donor (A11+DENV-) as well as healthy PBMC spiked with an epitope-specific 
CD8+ T cell line as a positive control to help place tetramer-positive gates (Figure 3.1A).  
Figure 3.1B shows flow cytometry plots comparing pD1 versus pD2 and pD1 versus 
pD3/4 tetramer staining of T cells in PBMC of a single donor obtained at multiple time 
points from acute infection until 1 year post-defervescence.  The mean±SD background 
tetramer staining for 12 healthy, A11+ DENV-naïve subjects was 0.095±0.079%.  A 
positive cutoff for tetramer frequencies was defined as any frequency greater than the 
tetramer frequency measured for 11 of the 12 A11+DENV- subjects (92nd percentile, 
>0.14%).  A11-NS3133 tetramer-positive CD8+ T cells were detected at one or more time 
points and increased over time to a distinct peak in 36 DENV-infected subjects (Figure 
3.1C and D).  Peak frequencies in these 36 subjects ranged from 0.15% to 19% with a 
median of 0.74% (mean = 2.33%; Figure 3.1E).  Of the 8 subjects without a detectable 
response above the cutoff, 3 subjects had data from no or one sample during the acute 
infection and 3 subjects were missing data for one of the tetramer variants; only 2 
subjects with adequate data failed to show an epitope-specific T cell response (one of 
whom had a peak frequency of 0.14%).  In some individuals, the tetramer-positive CD8+  
Figure 3.1. A11-NS3133-specific T cells expand 
in acute infection. 
(A) The gating strategy used to identify 
tetramer+CD8+ T cells started by selecting cells 
within the lymphocyte gate as defined by 
forward and side scatter profiles.  Live cells were 
next selected by exclusion of the viability marker 
LIVE/DEAD Aqua. T cells were identified by 
dual CD3 and CD8 expression followed by 
gating for singlet cells. (B) Tetramer staining of 
PBMC from an individual subject over the 
course of acute illness and convalescence. Days 
are relative to the day of defervescence (d0). (C) 
Tetramer+CD8+ T cell frequencies in PBMC 
from subjects with primary (n=17) or (D) 
secondary (n=22) DENV infection. Each colored 
line represents a single individual tracked over 
time. The black line represents the frequency of 
background tetramer staining measured for 11/12 
A11+DENV-naïve subjects (=0.14%).
Continued on next page
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Figure 3.1. A11-NS3133-specific T cells expand in acute infection. (cont’d)
...(E) Zebra plots show the peak frequency of A11-NS3133 epitope-specific T cells for 36 subjects, 
arranged according to the serotype of infection and whether the subject had a primary or secondary 
infection.  Tetramer staining of PBMC from an A11+DENV-naïve subject is also shown.  PBMC 
from each subject was stained simultaneously with all three tetramer variants; the two plots show 
pD1 versus pD2 and pD1 versus pD3/4 tetramer staining.  Numbers represent the frequency of 
total CD8+ T cells.  Subject ID numbers are included on top and to the right of the respective flow 
plots.  Flow plots are shown with large-sized dots.
E  (cont’d)
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T cell frequency changed rapidly, with large increases and decreases even in consecutive 
(daily) blood samples.  Although pre-infection PBMC samples were not available for this 
cohort, tetramer-positive CD8+ T cell frequencies were higher in acute infection and early 
convalescence than in late convalescence (≥6 months post-infection).  Sixteen of 20 
subjects with samples available from 1 year post-infection (and a distinct peak frequency 
during acute infection) showed an average contraction of 76% of A11-NS3133 tetramer-
positive T cells at the 1 year time point.  Four subjects had the same or higher tetramer-
positive CD8+ T cell frequencies at 1-3 years post-infection (compared to their peak 
frequency during acute infection) but had 16-65% contraction of epitope-specific T cells 
at 6 months post-infection; the possibility of subsequent DENV infection in these cases 
cannot be excluded. 
 
B. T cell expansion in acute DENV infection is antigen-specific 
We considered that conclusions based on the analysis of a single DENV epitope 
might not be generalizable or could reflect non-specific rather than antigen-specific T cell 
expansion.  To address the first possibility, we sought to analyze the frequency of T cells 
specific to another DENV epitope.  While a significant number of DENV T cell epitopes 
have been identified (Dung, et al., 2010; Vaughan, et al., 2010), lack of definition and 
low population frequencies of the restricting HLA alleles limit their utility; fortunately, 
we had pMHC tetramers available for an HLA-B7-restricted epitope (NS3222-231) we 
previously defined as immunodominant in HLA-B7+ Thai subjects (Mathew, et al., 
1998). 
Figure 3.2. T cell expansion in acute DENV infection is antigen-specific.
(A) Line graphs show frequencies of A11-NS3133 tetramer (pD1; blue) and B7-NS3222 multimer 
(B7-DENV; green) positive T cells from 5 HLA-A11+B7+ individuals throughout acute illness and 
convalescence.  (B) Line graphs show frequencies of pD1 tetramer (blue) and A2-Flu M158
multimer (A2-Flu; orange) positive T cells from 6 HLA-A11+A2+ individuals throughout acute 
illness and convalescence.  Days are relative to the day of defervescence (d0).
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  We therefore compared the frequencies of A11-NS3133 (pD1
+) and B7-NS3222 
tetramer-positive T cells in a subset of A11+B7+ subjects (n=5) in order to determine their 
relative contributions to the overall anti-viral CD8+ T cell response (Figure 3.2A).  These 
frequencies were similar in magnitude (each tetramer population was <2.5% of total 
CD8+ T cells), although the frequencies of B7-NS3222-specific CD8
+ T cells were 
consistently higher in 4 of the 5 subjects studied.  Both populations of epitope-specific T 
cells were present at higher frequency during acute infection than in late convalescence. 
To investigate whether DENV epitope-specific T cells were selectively expanded, 
we compared the frequency of A11-NS3133-specific T cells to that of T cells specific for 
the immunodominant HLA-A*0201-restricted influenza virus (Flu) M158-66 epitope 
(Figure 3.2B) (Bednarek, et al., 1991; Morrison, et al., 1992).  A2-Flu M158 tetramer-
positive CD8+ T cells were present at high frequency, consistent with previous findings 
(Gianfrani, et al., 2000), but decreased in frequency during acute DENV infection 
coincident with the increase in frequency of DENV epitope-specific CD8+ T cells.  This 
demonstrates selective expansion of antigen-specific T cells during acute DENV 
infection and implies that there was minimal contribution of bystander cells to the 
observed T cell response. 
 
C. Epitope-specific T cell frequencies peak earlier in primary than in secondary 
DENV infection 
Previous studies have yielded conflicting conclusions regarding the timing of 
expansion of DENV-specific T cells.  In this cohort, epitope-specific T cells generally  
No. subjects
Primary          Secondary
Fever day ≤0b 4 1
Fever day +1 1 8d
Fever day +7c 1 6
Table 3.2. A11-NS3133 tetramer frequencies 
peak earlier in primary DENV infectiona.
aThis analysis only considered those subjects for 
whom we had blood samples from all three of these 
time points (n=21)
bOne primary subject had peak tetramer frequency 
at fever day -2
cThe actual day post-defervescence differed for 
each donor (range=4-12, mean=7)
dThe difference between day 0 and day +1 is 
significant by Fisher’s exact test (p=0.02)
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peaked in frequency around defervescence or early convalescence before declining 
(Figure 3.1B-D), corresponding to the usual kinetics of viral clearance in acute DENV 
infections (Vaughn, et al., 1997; Vaughn, et al., 2000; Libraty, et al., 2002a).  Among 21 
subjects with samples available from fever days 0, +1 and +7, tetramer-positive CD8+ T 
cell frequencies were highest on the day of defervescence (fever day 0) or earlier in 5 
subjects, on fever day +1 in 9 subjects, and at the 1 week follow-up visit in 7 subjects 
(Table 3.2).  To determine whether prior DENV infection influenced the kinetics of the T 
cell response to acute infection, we determined when the peak frequency of A11-NS3133 
tetramer-positive CD8+ T cells occurred for individuals experiencing either a primary or 
secondary infection (Table 3.2).  Epitope-specific T cell frequencies in patients with 
primary infections peaked during acute infection, with the majority of peak responses 
detected on the day of defervescence (fever day 0).  Surprisingly, tetramer-positive T cell 
frequencies peaked later in patients with secondary DENV infection, typically one day or 
within one week after defervescence (p=0.02 for the difference in timing of peak 
frequencies between primary and secondary subjects at fever days 0 and +1, Table 3.2).   
 
D. The frequency of A11-NS3133 tetramer-positive T cells does not correlate with 
clinical findings 
Some previous studies reported that the magnitude of the DENV-specific T cell 
response correlates with disease severity (Zivna, et al., 2002; Mongkolsapaya, et al., 
2003; Mongkolsapaya, et al., 2006).  We examined this question in the present cohort, 
which included both primary and secondary donors with varying disease severity.  As  
B p = 0.08 p = 0.09
C
D
E
F
Day 0 Day +1 Day +7
Figure 3.3. The magnitude of A11-NS3133 epitope-specific T cells does not correlate with 
disease severity. 
(A) A11-NS3133 tetramer+CD8+ T cell frequencies are shown for individuals at fever day 0, +1 or 
+7.  Data are classified according to disease severity: DF=dengue fever, DHFI-III=dengue 
hemorrhagic fever grades I, II, or III.  Peak A11-NS3133 tetramer+CD8+ T cell frequencies are 
plotted versus (B) clinical diagnosis (DF versus DHF) and type of infection (primary versus 
secondary), (C) pleural effusion index, (D) % change in hematocrit, (E) maximum aspartate 
aminotransferase (AST) value and (F) minimum platelet count.  No significant correlations were 
detected by Mann-Whitney (B) or Spearman’s test (C-F). 
A
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symptoms of severe disease typically occur around defervescence (fever day 0) we 
compared the frequency of A11-NS3133 tetramer-positive T cells and disease severity at 
fever day 0, fever day +1 and 1 week after defervescence (Figure 3.3A).  We detected no 
correlation between tetramer-positive T cell frequency and clinical diagnosis (DF versus 
DHF) at any of these time points.  Among subjects with DF, peak tetramer-positive T cell 
frequencies were slightly higher in secondary infection than primary infection, but this 
difference did not reach statistical significance (p=0.08; Figure 3.3B).  Among subjects 
with secondary DENV infections, peak tetramer frequencies were slightly higher in 
subjects with DF than those with DHF, but this difference was also not statistically 
significant (p=0.09, Figure 3.3B).  No significant differences were found between 
subjects with primary DF and either primary DHF or secondary DHF.  We also tested 
whether peak tetramer-positive T cell frequencies correlated with measures of disease 
severity such as pleural effusion index (Figure 3.3C), percent change in hematocrit 
(Figure 3.3D), maximum aspartate aminotransferase values (Figure 3.3E) and minimum 
platelet count (Figure 3.3F), and found no significant correlations. 
 To investigate whether other DENV epitope-specific T cells correlated with 
clinical diagnosis, we assessed the frequency of B7-NS3222-specific T cells in subjects 
with DF or DHF.  No significant differences were detected among HLA-A11+B7+ 
subjects with regard to diagnosis (Figure 3.4).  Among HLA-A11-B7+ subjects, those 
with DHF had higher frequencies of B7-NS3222 tetramer-positive CD8+ T cells than 
subjects with DF at all time points analyzed (Figure 3.4).  However, the number of 
subjects for this analysis was too small for statistical analysis (2 with DHF and 3 with  
HLA-A11+B7+ donors HLA-A11-B7+ donors
DF
DHF
Figure 3.4. HLA-A11 may influence the expansion of B7-NS3222 epitope-specific T cells. 
B7-NS3222 tetramer frequencies for HLA-A11+B7+ or HLA-A11-B7+ donors with a final diagnosis 
of DF (blue lines) or DHF (red lines) are plotted over time.  Days are relative to the day of 
defervescence (d0).
DF
DHF
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DF).  These findings suggest that the HLA-A*1101 allele may influence the expansion of 
HLA-B*07-restricted NS3222 epitope-specific T cells in DENV-infected individuals. 
 
E. A11-NS3133-specific T cells are cross-reactive to multiple serotypic variants in 
both primary and secondary DENV infection  
Previous studies found that PBMC from subjects with secondary DENV infection 
preferentially bound to A11-NS3133 pMHC tetramers specific for heterologous DENV 
serotypes, suggesting that the T cell repertoire reflected “original antigenic sin” related to 
the prior infection (Mongkolsapaya, et al., 2003).  We reasoned that the effect of prior 
infections would only be evident by comparing the patterns of tetramer staining in PBMC 
from subjects with primary and secondary infection with different DENV serotypes.  
Based on the model of original antigenic sin, we expected that PBMC from primary 
donors would primarily bind homotypic tetramers whereas secondary donor PBMC 
would bind both homotypic and heterotypic tetramer variants.   
 Patterns of triple tetramer staining were analyzed according to the Boolean gating 
strategy outlined in Figure 3.5.  The distribution of tetramer staining among epitope-
specific T cells varied less across time points from the same individual than between 
individuals, but PBMC from subjects with primary infection (Figure 3.6A-C) displayed 
similar levels of heterotypic tetramer binding as PBMC from subjects with secondary 
infection (Figure 3.6D-G).  Of tetramer-positive T cells detected at 1 week post-
defervescence, median values of 67% and 72% (p=0.44) bound tetramers specific for 
heterologous serotypes in primary and secondary infection, respectively.   
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Figure 3.5. Outline of the gating strategy to identify tetramer-positive 
T cell subsets. 
The Boolean gating strategy used to identify the distribution of sub-
populations of tetramer+ T cells within the live, CD3+CD8+ singlet 
lymphocyte population (refer to Figure 3.1A) and the resulting pie chart. 
The four outer dot plots are shown with large-sized dots. 
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Figure 3.6. Tetramer-positive T cells are highly serotype-cross-reactive in subjects with primary or 
secondary infection. 
The distribution of sub-populations within the whole population of A11-NS3133 tetramer+CD8+ T cells is 
depicted using pie charts.  Subjects with a (A-C) primary or (D-G) secondary infection with (A,D) DENV-
1, (B,E) DENV-2, (C,F) DENV-3 or (G) DENV-4 are shown.  No subjects with primary DENV-4 
infection were available.  Pie charts are shown for those time points with data from at least 20 tetramer-
positive T cells (mean and median number of tetramer+CD8+ T cells per sample = 435 and 164, 
respectively).  Each row represents data from a single donor over time.  Time points shown are relative to 
the day of defervescence (d0), d = day, w = week, m = month, y = year. 
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The pMHC tetramer staining did not follow a consistent pattern according to the 
serotype of the infecting virus or clinical diagnosis.  However, there were some 
similarities among subjects within a particular donor group.  For example, there was a 
greater percentage of pD2+ cells (shown in yellow) in subjects with primary DENV-3 
infections compared to those with secondary DENV-3 or DENV-1 infections, whether 
primary or secondary, at 1 week post-infection (median = 15% versus 5% and 6%, 
respectively; p<0.01).  Additionally, subjects infected with DENV-1(whether during 
primary or secondary infection) had a greater percentage of pD3/4+ cells (shown in red) 
than those infected with DENV-3 (median = 30% versus 13%; p=0.04) at fever day +1.  
Relatively few T cells bound to two or more tetramers at once (shown in green, purple, 
orange and brown) and were more often found in subjects with secondary infections than 
those with primary infections (median = 6% for primary versus 11% for secondary at 1 
week, p=0.07).  These observations support previous indications that the sequence of 
infection influences the DENV-specific memory CD8+ T cell pool (Bashyam, et al., 
2006; Beaumier, et al., 2008).   
This analysis also revealed a prevalence of T cells that bound the pD1 tetramer 
(shown in blue).  To exclude the possibility that this was an artifact of our staining 
conditions, we compared staining with all three tetramer variants at once to staining with 
each variant individually (Figure 3.7A and B).  The frequency of tetramer-positive T cells 
was slightly different between the two staining conditions, indicating some competition 
amongst the variants.  Nevertheless, the relative staining pattern with particular tetramer 
variants was comparable.  We also tested whether decreasing the concentration of one  
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Figure 3.7. The prevalence of pD1 tetramer binding by patient PBMC is not an artifact of 
staining conditions. 
Flow plots show repeated tetramer staining of PBMC from four subjects which were stained 
with each of the three A11-NS3133 tetramer variants (A) together (“triple tetramer staining”) or 
(B) alone (“single tetramer staining”).  Numbers inside each plot indicate the frequency of total 
CD8+ T cells.  Subject ID numbers are included to the right of each row of respective flow plots.  
(C) An epitope-specific T cell line which stains with pD1 and pD3/4 tetramers was subject to 
triple tetramer staining conditions in which the concentration of pD1 or pD3/4 tetramer was 
decreased while the concentration of the other two tetramers remained constant.
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tetramer while keeping the other tetramer concentrations constant would influence the 
frequency of T cells that bound to particular tetramer variants.  Using an A11-NS3133 
epitope-specific T cell line which binds the pD1 and pD3/4, but not pD2, tetramers, we 
reduced the concentration of pD1 or pD3/4 by nearly 10-fold but detected no differences 
in the frequency of cells that bound to the other tetramer variants (Figure 3.7C).   
The pie chart analysis, while informative, does have limitations.  For example, 
quadrant gates were placed based on positive and negative controls, which do not take 
into account subject-to-subject variation.  The flow plots shown in Figure 3.1E 
demonstrate that for some subjects (e.g. subject C96-045), pD1 tetramer-positive T cells 
seem to ‘lean’ toward the pD3/4 tetramer-positive gates, but do not meet the threshold 
used to count them as pD3/4 tetramer-positive (pD1+3/4+); these cells would thus show 
up as pD1+ (blue) in the respective pie chart (if we do not consider pD2 tetramer 
staining).  To account for this, the intensity of pD3/4 tetramer staining of all pD1 
tetramer-positive CD8+ T cells, relative to total tetramer-negative CD8+ T cells, was 
compared across all time points for subjects with primary versus secondary DENV-3 
infections (Figure 3.8).  No differences were detected between these subject groups, 
further supporting our finding that the extent of serotype-cross-reactivity does not differ 
according to DENV infection history.   
Another limitation of the pie chart analysis regards the use of the Mann-Whitney 
rank sum test to assess differences in the presence of particular epitope-specific T cell 
subsets (e.g. pD1+, pD1+3/4+) between groups of subjects (e.g. primary/secondary, 
serotype of infection).  This is a non-parametric test that accounts for the large amount of  
Figure 3.8. The intensity of pD3/4 tetramer staining of pD1 tetramer-positive T cells 
does not differ in subjects with primary versus secondary infection. 
Shown is the gMFI of PE (pD3/4) fluorescence for all pD1+CD8+ T cells, relative to total 
tetramer-negative CD8+ T cells, for subjects with a primary (blue) or secondary (orange) 
DENV-3 infection.  Each line represents a single subject over time.  Days are relative to 
the day of defervescence (d0).
DENV-3 immune subjects
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variation within our samples; however, the test is based on the ranks of the data and not 
the actual values.  Additionally, our study was not powered to detect specific size effects 
between subject groups.  Future studies should be powered to appropriately test the 
differences seen in our study.  A further limitation of our analysis was the exclusion of 
subjects that did not have a viable sample for the time point chosen for comparison.  The 
explanations for not having a sample at this time point include failure to obtain a sample, 
insufficient sample size, and/or viability issues pertaining to that particular sample.  For 
these reasons, we cannot exclude the possibility of selection bias in our results. 
To support the finding of preferential binding of T cells to heterologous tetramers 
in primary DENV infections, we assessed cytokine responses in a subset of PBMC 
samples by intracellular cytokine staining (ICS) after peptide stimulation.  We detected 
variable responses in PBMC from children with primary or secondary DENV-3 
infections (Figure 3.9).  Flow plots show the A11-NS3133 epitope-specific T cell response 
for a representative subject with secondary infection (Figure 3.9A).  PBMC from some 
subjects with primary DENV-3 infections responded to stimulation with heterologous 
epitope variants (pD1 and pD2) more than to the homologous peptide (pD3/4; Figure 
3.9B); these responses seemed to change with time, consistent with the temporal 
evolution of tetramer binding seen for some subjects (Figure 3.6).  The patterns of 
responses were similar in PBMC from subjects with secondary DENV-3 infections, 
though pD3/4-specific responses appeared higher than in subjects with primary infection 
(Figure 3.9C).  These functional data, while limited, support the findings based on  
Figure 3.9. Peptide-stimulated PBMC from subjects with primary or secondary infection 
demonstrate serotype-cross-reactive T cell functional responses.
(A) Representative flow plots show degranulation (CD107a) and production of cytokines (MIP-1β, 
TNFα, IFNγ) by DENV-immune PBMC (subject C96-016) after no stimulation (NS) or 
stimulation with anti-CD3/28 (positive control) or 10µg/mL of pD1, pD2, or pD3/4 for 6 hours in 
an intracellular cytokine staining (ICS) assay.  Flow plots are shown with large-sized dots.  Bar 
graphs show the response detected by ICS from PBMC from subjects with (B) primary DENV-3 
infections obtained 1 week or 6 months post-defervescence, or (C) secondary DENV-3 infections 
obtained 1 week post-defervescence.  
Continued on next page
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Figure 3.9. Peptide-stimulated PBMC from subjects with primary or secondary infections 
demonstrate serotype-cross-reactive T cell functional responses. (cont’d)
...Shown are frequencies (relative to NS) of total CD8+ T cells that responded to each peptide 
variant by degranulation (CD107a; red) or production of MIP-1β (blue), TNFα (green), or IFNγ
(purple).  Subject ID numbers are included in the top-right-hand corner of each bar graph.
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patterns of tetramer binding, indicating striking cross-reactivity in primary DENV 
infections. 
 
F. Antigen-specific CD8+ T cells are highly activated during acute DENV infection 
Previous data suggested that T cells were more highly activated in severe dengue 
disease (Green, et al., 1999a; Chau, et al., 2008).  However, a recent report concluded 
that CD38-expressing CD8+ T cells did not appear until after viral clearance and 
suggested that DENV-specific T cells could therefore not contribute to severe disease 
(Dung, et al., 2010).  Since our study showed high frequencies of A11-NS3133-specific T 
cells during acute infection, we examined CD38 expression to assess whether antigen-
specific T cells were differently activated in primary versus secondary infection and if 
levels of T cell activation correlated with outcome. 
We detected high CD38 expression in total CD8+ T cells and even higher 
expression in epitope-specific T cells during acute infection and shortly after 
defervescence (Figure 3.10A).  While levels of CD38 expression varied across 
individuals (Figure 3.10B), the average geometric mean fluorescence intensity (gMFI) of 
tetramer-positive T cells in PBMC from the four subject groups (primary DF, primary 
DHF, secondary DF and secondary DHF) showed similar patterns over time (Figure 
3.10C).  CD38 expression was slightly higher in subjects with secondary versus primary 
infection during acute illness; however, this difference did not achieve statistical 
significance (Figure 3.10D).   
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Figure 3.10. Antigen-specific T cells are highly activated during acute DENV infection and early 
convalescence. 
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Figure 3.10. Antigen-specific T cells are highly activated during acute DENV infection and early 
convalescence. (cont’d)
(A) Representative histograms show the expression of CD38 over time in total CD8+ T cells from an 
A11+ DENV-infected donor (dark blue line) as well as A11-NS3133 tetramer+CD8+ T cells from the 
same DENV-infected donor (light blue line).  Also shown is CD38 expression of total CD8+ T cells 
from a healthy A11+ donor (shaded).  (B) The fold change in geometric mean fluorescence intensity 
(gMFI) of CD38 expression in tetramer+CD8+ T cells from individuals experiencing either a primary 
(1º) or secondary (2º) DENV infection with DF or DHF.  Each colored line represents a single subject 
over time.  Numbers are relative to total CD8+ T cells from a healthy control donor included in each 
experiment.  (C) The mean fold change in gMFI of CD38 staining in A11-NS3133 tetramer+CD8+ T 
cells from subjects with 1º (solid lines) or 2º (dotted lines) DENV infections with either DF (closed 
circles) or DHF (open squares) over time.  Data are relative to the gMFI of CD38 of total CD8+ T cells 
from a healthy control donor included in each experiment.  (D) Fold change in gMFI of CD38 is shown 
for 1º DF, 1º DHF, 2º DF and 2º DHF donors at fever days -2 and +1.  Bars indicate median values for 
each group.  Differences were not statistically significant by Mann-Whitney test.  (E) Representative 
dot plots from a DENV-infected individual show the expression of Ki-67 and Bcl-2 in tetramer+CD8+ T 
cells (blue) compared to total CD8+ T cells (black).  Dot plots are shown with large-sized dots.  Each 
pair of colored lines on the graph represents tetramer+CD8+ T cells from a single individual over time 
and their expression of Ki-67 (filled circles) or Bcl-2 (open squares).  (F) Dot plots show the 
expression of granzyme B in live, CD3+CD8+ singlet T cells over time for a DENV-infected individual.  
Each line on the graph represents granzyme B expression by tetramer+CD8+ T cells from an individual 
patient over time.  (G) Overlaid histograms show the expression of CD69 over time of tetramer+CD8+
T cells (light blue line) and total CD8+ T cells (dark blue line) from a DENV-infected individual 
relative to total CD8+ T cells from a healthy control donor included in the experiment (shaded 
histogram).  Each line on the graph represents the percentage of CD69+tetramer+CD8+ T cells from a 
single subject over time.  Days are relative to the day of defervescence (d0).
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Figure 3.11. Antigen-specific T cells are preferentially activated during acute 
DENV infection and early convalescence. 
(A) The mean fold change in gMFI of CD38 expression in pD1+CD8+ T cells 
(blue), A2-Flu+CD8+ T cells (orange) and total CD8+ T cells (purple) over time in 
HLA-A2+A11+ subjects (n=6).  Bars indicate standard deviation at each time point.  
(B) The mean fold change in gMFI of CD38 expression in pD1+CD8+ T cells 
(blue), B7-DENV+CD8+ T cells (green) and total CD8+ T cells (purple) over time 
in HLA-A11+B7+ subjects (n=5).  Bars indicate standard deviation at each time 
point.  Days are relative to the day of defervescence (d0).
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Decreasing CD38 expression one week post-defervescence coincided with a 
decrease in Ki-67 (a marker of proliferation) and Bcl-2 (an anti-apoptotic marker) 
expression (Figure 3.10E).  Granzyme B, on the other hand, remained highly expressed in 
tetramer-positive T cells as well as a subset of tetramer-negative CD8+ T cells late into 
convalescence (Figure 3.10F).  CD69 expression was only detected prior to 
defervescence (Figure 3.10G), consistent with a previous study (Green, et al., 1999a).   
As the majority of CD8+ T cells (both tetramer-positive and tetramer-negative) 
appeared to up-regulate CD38 expression, we compared the relative activation of DENV-
specific T cells and T cells specific for other non-dengue antigens in order to assess the 
selectivity of this effect.  We found that CD38 expression on A2-Flu M158-specific CD8+ 
T cells was slightly increased during acute DENV infection (Figure 3.11A); however, the 
average increase in gMFI on these cells was much lower than on DENV-specific T cells 
detected by either A11-NS3133 or B7-NS3222 pMHC tetramers (Figure 3.11B).  These 
data suggest that, while T cells specific for other antigens are activated to an extent, there 
is a preferential activation of DENV-specific T cells. 
 
G. Evolution of T cell phenotypes follows different kinetics in primary versus 
secondary DENV infection 
The phenotypic classification of naïve, effector and memory CD8+ T cell subsets 
and the paradigm of their evolution continue to be refined.  Nevertheless, the expression 
of CD45RA, CCR7, and/or CD127 has been used previously and provides a point of 
reference for comparison to studies of other human viral infections  
Figure 3.12. Effector-to-memory phenotypic evolution of epitope-specific T cells in DENV-
infected subjects. 
(A) Overlaid flow plots show the expression of CD45RA versus CCR7 of total CD8+ T cells 
(black; density plots) and A11-NS3133 tetramer+CD8+ T cells (blue; dot plots shown with large-
sized dots) over time in PBMC from representative subjects with primary (1º) or secondary (2º) 
infections.  (B) The percentage of CD45RA+tetramer+CD8+ T cells from subjects with primary 
(solid lines) and secondary (dotted lines) DENV infections with either DF (closed circles) or DHF 
(open squares) over time.  Data are presented as means within each subject group.
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Figure 3.12. Effector-to-memory phenotypic evolution of epitope-specific T cells in DENV-
infected subjects. (cont’d)
...(C) Line graphs show frequencies of tetramer+CD8+ T cells expressing CD45RA, CCR7 or 
CD127 over time.  Each line represents an individual subject.  The donors are grouped according to 
serologic response (primary [1º] or secondary [2º]) and clinical diagnosis (DF or DHF).  Days are 
relative to the day of defervescence (d0).
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(Precopio, et al., 2007; Miller, et al., 2008; Akondy, et al., 2009).  We therefore assessed 
the expression of these markers by DENV-specific T cells to compare the evolution of T 
cell phenotype over time in primary and secondary infections. 
 The expression of CD45RA and CCR7 declined on both tetramer-positive and 
total CD8+ T cells during acute infection followed by re-expression of both markers in 
convalescence (Figure 3.12A).  The decline of the frequency of CD45RA+ tetramer-
positive T cells during acute infection was consistent across all four subject groups 
(primary DF, primary DHF, secondary DF, secondary DHF), reaching its nadir in early 
convalescence; these changes occurred slightly earlier and to a greater extent in subjects 
with secondary infection compared to those with primary infection (Figure 3.12B).  
CD45RA expression rebounded with similar kinetics on tetramer-positive T cells from all 
subjects by 6 months to 1 year post-infection.  A relatively low frequency of tetramer 
positive T cells expressed CD127 during acute infection, which appeared to start 
increasing late into convalescence (Figure 3.12C).   
 
H. Chapter summary 
 Serotype-cross-reactive memory T cells reactivated during a secondary 
heterologous DENV infection have been hypothesized to help trigger severe 
manifestations of dengue disease.  We compared the frequency, kinetics and phenotype 
of DENV epitope-specific T cells in a pediatric Thai cohort undergoing naturally-
acquired primary or secondary DENV infections.  Using peptide-MHC tetramers specific 
for two previously identified immunodominant DENV epitopes, together with activation 
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and phenotypic markers, we performed a longitudinal analysis of epitope-specific CD8+ 
T cells in PBMC of a large cohort of patients during, immediately following and up to 
three years after acute infection.  We detected robust expansion of HLA-A*1101-
restricted NS3133-142 and HLA-B*07-restricted NS3222-231-specific T cells with an 
activated phenotype during and shortly after the febrile phase in PBMC of patients with 
both mild and severe disease.  No correlation was found between A11-NS3133 T cell 
frequency and disease severity.  Contrary to our expectations, patients with primary 
infection had high frequencies of serotype-cross-reactive T cells, indicating that 
heterotypic tetramer binding is not only a result of secondary infections.  Our study 
demonstrates that activated T cells are present during acute DENV infection, supporting 
the potential for them to contribute to the pathogenesis of dengue disease; however, the 
frequency of T cells specific for any single epitope is not the principal determinant of 
disease severity.  
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CHAPTER IV 
MEMORY CD8+ T CELLS FROM SUBJECTS WITH NATURALLY-ACQUIRED 
PRIMARY DENGUE VIRUS INFECTION ARE HIGHLY CROSS-REACTIVE 
 
 Our laboratory and others have demonstrated the ability of DENV-specific T cells 
to recognize multiple DENV serotypes.  Most of these studies analyzed PBMC either 
from donors that received candidate live-attenuated monovalent vaccines or naturally-
infected patients who experienced a secondary DENV infection.  One recent study 
reported cytokine secretion and degranulation from epitope-specific T cells directly ex 
vivo from the PBMC of naturally-infected Thai children (Duangchinda, et al., 2010).  Our 
data in Chapter III also demonstrated cytokine secretion directly ex vivo in Thai children 
with natural primary infections.  We found that these T cell responses occurred after 
stimulation with peptide variants specific for heterologous serotypes to a greater extent 
than after homologous stimulation.  T cells from subjects with primary infection are 
primed to respond in secondary DENV infection, so it is of particular importance to 
analyze the mechanisms that naturally-generated memory DENV-specific T cells use to 
respond to homologous versus heterologous serotypes.   
We wanted to extend our ex vivo observations of serotype-cross-reactivity by 
investigating the breadth of CD8+ T cells that comprise the A11-NS3133 epitope-specific 
response.  We also investigated whether the three A11-NS3133 epitope variants induce 
different signals that result in different functional outcomes.  We studied homologous and 
heterologous T cell responses in primary DENV-immune PBMC after short-term bulk 
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culture and isolated epitope-specific CD8+ T cell lines to determine functional serotype-
cross-reactivity at the T cell clonal level. 
 
A. Cross-reactive T cells expand after homologous and heterologous stimulation of 
PBMC from primary DENV-immune subjects 
 Since frequencies of virus-specific T cells are low ex vivo, we wanted to assess 
functional responses after short-term bulk culture.  HLA-A11 is a prevalent haplotype in 
DENV-endemic regions (in particular, Thailand) so we decided to use serotype-specific 
variants of the A11-NS3133 DENV epitope (Mongkolsapaya, et al., 2003) to expand 
epitope-specific T cells in vitro.  The DENV-2 variant (pD2) as well as the DENV-3 and 
-4 variant (pD3/4) each differ from the DENV-1 variant (pD1) by a single amino acid 
(refer to Table 2.1).  We used convalescent PBMC from four DENV-immune HLA-
A*1101+ individuals (Table 4.1).  Donor 1 was immunized with a live-attenuated, 
experimental DENV-1 vaccine and was included due to a well-defined DENV infection 
history and the availability of large sample volumes.  We also had access to large sample 
volumes from donor 2, who experienced a naturally-acquired DENV infection several 
years prior; the details of the subject’s serotype of infection or DENV infection history 
were unknown.  Donors 3 and 4 were Thai subjects with natural primary DENV-3 
infections for whom we also had data from the ex vivo study (Chapter III).  For this study, 
PBMC from each subject were stimulated with each of the three epitope variants.   
 After approximately two weeks in culture, pMHC tetramer staining of bulk 
cultures from all four subjects revealed a modest enrichment of epitope-specific CD8+ T  
Donor Serology Serotype (Exposure) Diagnosis
a Age 
Rangeb
Country 
of Origin
MHC Class I     
A            B            C
Time point 
of PBMCc
1 Primary DENV-1 (vaccine) n/ad Adult U.S.A. 2,11       27,40       1,3 8 months
2 Unknown Unknown (natural) DF Child Philippines 11,24       35,40       7,7 Years
3 Primary DENV-3 (natural) DHF I Child Thailand 2,11       13,38        7 6 months
4 Primary DENV-3 (natural) DHF II Child Thailand 11,24       18,54       7,8 1 week
Table 4.1. Summary of HLA-A*1101+ primary DENV-immune subjects and clinical information.
aaccording to WHO guidelines; DF = dengue fever, DHF = dengue hemorrhagic fever
bat time of infection
cpost-defervescence
dsubject experienced mild dengue-like illness post-vaccination; see Green, et al., 1993
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FIGURE 4.1. A11-NS3133 peptide-stimulated bulk cultures from four A11+ DENV-immune 
subjects demonstrate serotype-cross-reactivity with preference for the DENV-1 variant pMHC
tetramer. 
After approximately two weeks, peptide-stimulated bulk cultures from (A) donor 1, (B) donor 2, (C) 
donor 3, or (D) donor 4 were stained with epitope-specific pMHC tetramers.  Shown is dual tetramer 
staining (pD1/pD2 or pD1/pD3/4) for donor 1 bulk cultures and triple tetramer staining 
(pD1/pD2/pD3/4) for donors 2, 3, and 4 bulk cultures.  
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cells (Figure 4.1).  Regardless of the subject or peptide variant used for stimulation, 
nearly all of the expanded tetramer-positive T cells bound the DENV-1 variant tetramer.  
Therefore, to increase the frequency of epitope-specific T cells, we magnetically sorted 
for pD1 tetramer-positive cells.  For donor 1 (1º DENV-1), we tetramer-sorted half of 
each bulk culture (followed by non-specific anti-CD3 stimulation) while we re-stimulated 
the other half with the same peptide variant originally used.  Subsequent tetramer staining 
revealed complex patterns of serotype-cross-reactive T cells, which were similar 
regardless of whether the bulk culture was tetramer-sorted or unsorted (though epitope-
specific T cell frequencies were higher in the sorted bulk cultures; Figure 4.2a and b).  T 
cells expanded by pD1 stimulation had pD1+ and pD1+2+ or pD1+3/4+ populations, as 
determined by dual tetramer staining (pD1/pD2 tetramer staining or pD1/pD3/4 tetramer 
staining).  T cells expanded by pD2 or pD3/4 stimulation also showed pD1+ T cells when 
stained with pD1/pD2 tetramers, but the majority of these appeared to be pD1+3/4+ when 
stained with pD1/pD3/4 tetramers.  These data suggested that only pD1 stimulation could 
expand pD1 serotype-specific (pD1+) T cells, in addition to serotype-cross-reactive 
(pD1+2+ and pD1+3+) T cells, whereas pD2 and pD3/4 stimulation mostly expanded 
serotype-cross-reactive T cells.  However, single tetramer staining of the sorted bulk 
cultures with the pD3/4 tetramer indicated (by comparison of frequencies) that the “pD1 
serotype-specific” (pD1+) T cells were actually serotype-cross-reactive but of lower 
avidity for the pD2 and pD3/4 tetramers and preferentially bound the pD1 tetramer when 
it was present. 
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Peptide re-stimulation pD1 tetramer+ sort  anti-CD3 re-stimulation
FIGURE 4.2. A11-NS3133 peptide-stimulated bulk cultures from donor 1 show marked 
serotype-cross-reactivity with preference for DENV-1. 
After two weeks, peptide-stimulated bulk cultures from donor 1 were (A) re-stimulated with peptide 
or (B) magnetically sorted for pD1 tetramer+ cells before non-specific re-stimulation.  Shown is dual 
or single tetramer staining for each bulk culture.  (C) Unsorted or (D) tetramer-sorted bulk culture 
cells were incubated for 4 hours with 51Cr-labeled autologous BLCL coated with pD1 (blue), pD2 
(yellow), pD3/4 (red), or no peptide (black) to induce peptide-specific lysis.  This assay used an 
effector-to-target ratio of 25:1.
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 We also wanted to determine whether serotype-cross-reactive tetramer binding 
reflected cross-reactive functional responses (Figure 4.2c and d).  Tetramer-sorted bulk 
cultures lysed autologous B-lymphoblastoid cell line (BLCL) target cells coated with any 
of the three epitope variants, with the highest response to pD1+ BLCL.  Unsorted bulk 
culture cells were only able to lyse BLCL coated with pD1, whereas lysis of pD2+ or 
pD3/4+ BLCL was minimal (even in pD2 and pD3/4 stimulated bulk cultures).  Cytolysis 
of pD1+ target cells was lower in unsorted bulk cultures compared to tetramer-sorted bulk 
cultures at the same effector-to-target ratio, which may reflect the frequency of epitope-
specific T cells (which was substantially higher in the sorted bulks).  These findings 
suggest that sorting A11-NS3133 epitope-specific bulk cultures using the pD1 tetramer 
enriched for epitope-specific T cells and maintained the same pattern of tetramer staining 
and function as unsorted cells.   
 
B. CD8+ T cell lines isolated from subjects who had primary DENV infection 
demonstrate variable degrees of serotype-cross-reactivity 
We next wanted to isolate individual epitope-specific T cell clones to assess the 
breadth of cell types that compose the A11-NS3133-specific T cell repertoire.  We used 
the bulk cultures generated above to seed limiting dilution assay plates at 10 or 3 cells per 
well (Figure 4.3).  Epitope-specific T cell lines were chosen on the basis of their ability to 
selectively lyse peptide-coated HLA-A*1101+ BLCL target cells and were subsequently 
characterized with regard to peptide dose-dependent cytotoxicity as well as pMHC 
tetramer staining.   
FIGURE 4.3. Generation of A11-NS3133 epitope-specific T cell lines.
Protocol used to generate and isolate epitope-specific CD8+ T cells lines from the PBMC of four 
DENV-immune donors.  PBMC were stimulated with 10µg/mL of one of the three A11-NS3133
epitope variants to generate three peptide-specific bulk cultures.  Each bulk culture was 
magnetically-sorted for pMHC tetramer-positive T cells before seeding at 10 or 3 cells/well in 
limiting dilution assays.  Epitope-specific T cell lines were selected for further analysis on the basis 
of specific lysis of HLA-A*1101+ BLCL coated with A11-NS3133 peptide.
PBMC Bulk Culture
magnetic sort for
tetramer+ cells
+ pD1
+ pD2
+ pD3/4
10 cells/well 3 cells/well
Limiting Dilution
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We isolated three types of epitope-specific T cell lines: pD1 serotype-specific, 
pD1-3/4 cross-reactive, and pD1-2-3/4 cross reactive.  Data from representative cell lines 
are shown in Figure 4.4.  Each T cell line was stained with each individual tetramer in 
order to assess its ability to recognize the three peptide variants.  In general, pMHC 
tetramer binding reflected the ability to lyse target cells coated with the same peptide in 
51Cr release assays.    
Of the thirty-three cell lines that were established, the majority demonstrated 
serotype-cross-reactivity by pMHC tetramer staining regardless of the donor or bulk 
culture from which they originated (Table 4.2).  The extent of pMHC tetramer binding 
did not always predict the magnitude of the cytolytic response.  For example, the cell line 
10D6 from donor 3 demonstrated greatest binding to the pD1 tetramer while its cytolytic 
response was comparable toward targets coated with any of the three peptides.  In 
addition, the lack of binding to a given tetramer did not necessarily indicate that the cell 
line could not mount a functional response against that particular peptide variant.  For 
example, the cell line 10D7 did not bind the pD2 or pD3/4 tetramers yet demonstrated 
robust cytolysis of pD2 and pD3/4 peptide-coated target cells.  Notably, there were no 
cases in which a cell line bound a given tetramer and did not respond in 51Cr release 
assays towards BLCL coated with that particular peptide variant.  Thus, discrepancies 
between tetramer binding and cytolytic responses likely reflect lower avidity of a soluble 
pMHC tetramer compared to the pMHC complex presented on the surface of an antigen 
presenting cell. 
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FIGURE 4.4. Three predominant patterns of serotype-cross-reactivity amongst A11-NS3133-
specific T cell lines.
(A) Gating strategy used to identify tetramer+CD8+ T cells.  (B) Cell lines were stained with each 
of the three tetramer variants and reveal three types of serotype-cross-reactivity: pD1 serotype-
specific, pD1-3/4 cross-reactive, pD1-2-3/4 cross-reactive.  Cells were gated on live, CD3+ singlet 
lymphocytes.  (C) 51Cr release assays demonstrate peptide dose-dependent cytolytic activity of 
representative T cell lines at an effector-to-target ratio of 10:1.  NS = no stimulation.
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Donor
Peptide 
stimulation 
(bulk)
Cell line
Tetramer specificitya
pD1     pD2    pD3/4
[pD1]
% Specific Lysisb
[pD2] [pD3/4]
1 pD1c 10B4d +++         -- ++ 71       32      <0       <0 <0       <0       <0       <0 29       39       29      <0
10B8 ++         ++         ++ 59       --- --- --- 49       48       40       16 55       45       61       42
10D6d +++         -- ++ 58       34        5         1 1         0         0         1 40       37       28        3
10D12 +++         -- ++ 53       54       57       38 24       10        2         1 53       51       47       45
10E11 ++          -- -- 51       55       55       25 <0      <0       <0       <0 12        3       <0       <0
10H11d +++        ++          ++ 61       30        4         2 49       49       65       47 49       40       36       51
pD2 10A1d +++         -- ++ 49       35       13        9 37       28       27        1 44       44       41       50
10A3 +++        +/- + 49       56       70       60 44       44        9         2 57       84       59       87
10D7 ++          -- -- 50       55       62       37 37       27        8         1 49       78       45       65
10E12 +++        +/- +++ 76       66       57       43 61       57       24        3 97       86       86       81
10F9 +++         -- +/- 49       58       62       47 36       38       19        1 44       73       44       50
10H3 +++        +/- +++ 72       64       59       68 83       76       55       23 89       82       84       76
pD3/4 10A7d +++         -- ++ 13        0       <0         2 0       <0         1       <0 20       22       22       20
10D5d +++         -- ++ 57       48       16        5 31       25       36       10 41       34       37       41
10D9d +++         -- ++ 38       23      <0       <0 16       13       10      <0 18       20       22       30
10E5d +++         -- ++ 50       24        0         4 12        1         3       <0 38       34       36       41
10H7d +++         -- ++ 42       15        9         7 6         4         5         2 42       49       39       38
10H9d +++         -- -- 41       34       18        5 32       31       25        8 29       27       10        5
Table 4.2. Lytic activity and tetramer specificity of A11-NS3133 epitope-specific T cell lines.
Continued on next page
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Donor
Peptide 
stimulation 
(bulk)
Cell line
Tetramer specificitya
pD1     pD2    pD3/4
[pD1]
% Specific Lysisb
[pD2] [pD3/4]
2 pD1c 10D4d +           -- +++ 18        1         2         0 0         0       <0         1 26       27       19        2
pD2 3B3d ++          -- +++ 29        1         2       <0 1         2       <0         1 39       41       31       25
3C7d ++          -- +++ 27        0       <0         0 <0       <0       <0       <0 48       45       35       23
pD3/4 3D10d +++         -- +++ 19        0       <0       <0 <0       <0       <0       <0 24       21        6       <0
3G10d +++         -- +++ 24        1         1         3 <0       <0       <0         1 20       18        5       <0
3G11d +++         -- +++ 32        4       <0       <0 <0       <0       <0         2 27       19       14        2
3 pD3/4 10A6 +++        ++          + 54       61       45       71 66       38       42        5 37       62       39       23
10C6 +++         +          ++ 65       58       65       72 70       42       31        4 56       72       48       23
10D6 +++        +/- + 33       41       43       70 50       46       40        4 48       48       61       36
10F5 +++         +          ++ 68       71       60       92 48       31       28        5 56       52       50       29
10G5 +++         +          ++ 57       73       67       43 54       59       43        8 62       71       48       31
10H5 +++         +          ++ 62       64       47       66 48       23       31        4 54       45       50       28
4 pD3/4 10C1d +           -- + 44       17      <0       <0 <0         1         0       <0 32       38       46       56
10C11 +++         -- +++ 53       54       53       46 10        1       <0       <0 54       49       50       47
10F12 +++         -- +++ 59       60       60       35 <0        0         0         1 55       57       55       56
Table 4.2. Lytic activity and tetramer specificity of A11-NS3133 epitope-specific T cell lines (cont’d)
abased on staining with each tetramer variant individually;  --, did not bind tetramer; +/-, <%30 bound tetramer; +, <%60 bound tetramer; ++, 
<%90 bound tetramer; +++, ≥%90 bound tetramer
b[peptide] = 10, 1, 0.1, 0.01 µg/mL; numbers indicate average % specific lysis relative to negative (no peptide) control, n ≥ 3
cThis bulk culture was generated using the 11mer variant of the pD1 peptide, GTSGSPIVNRE, which was originally identified in 
Mongkolsapaya, et al., 2003
dData generated for this cell line using pD1 was performed with the 11mer variant of the pD1 peptide
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C. TCRs on A11-NS3133 epitope-specific T cells comprise select Vβ chains regardless 
of serotype specificity 
We wanted to analyze the Vβ gene segments that compose A11-NS3133 epitope-
specific TCRs in order to determine whether particular Vβ chains were associated with 
varying degrees of serotype-cross-reactivity, as had been suggested previously for a 
different DENV epitope (Livingston, et al., 1995).  Surface staining on selected T cell 
lines showed preference for three Vβ chain families: 8, 21.3 and 23 (Table 4.3).  No 
correlation was observed between particular Vβ chains and serotype-cross-reactivity 
profiles.   
 
D. The three A11-NS3133 epitope variants have different predicted peptide-MHC 
binding affinities 
 To ascertain potential differences in the ability of these epitope variants to bind 
HLA-A*1101, we employed three peptide-MHC binding prediction algorithms provided 
by the Immune Epitope Database and Analysis Resource website.  The three epitope 
variants were calculated to have comparable binding scores, though a consistent 
hierarchy of pD3/4 > pD1 >> pD2 did emerge (Table 4.4).  The differences between 
these peptides largely reflected the hierarchy of potency seen for them in 51Cr release 
assays with our epitope-specific CD8+ T cell lines. 
 
 
Serotype-cross-
reactive profilea Cell line
b Vβ chainc
pD1 serotype-specific 10E11 8
pD1-3/4 cross-reactive 10B4 8
10D12 21.3
10D4 21.3
3D10 23
3G11 23
10C1 21.3
10C11 21.3
10F12 8
pD1-2-3/4 cross-reactive 10B8 noned
10D5 21.3
Table 4.3. A11-NS3133-specific TCRs show 
preference for select Vβ chains.
aAs determined by patterns of tetramer staining and 
cytotoxicity
b8/11 cell lines stained ≥ 97% with a single Vβ
chain-specific antibody; 10B4 was ≥ 93% specific; 
10D5 was ~86% specific
cThe Vβ nomenclature system used here follows that 
by Wei, et al., 1994
dThis cell line was negative for the 24 Vβ chains 
included in the staining kit
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Table 4.4. Peptide-MHC binding predictions of A11-NS3133
epitope variants.
Peptide variant
MHC-I Binding Prediction (nM)a
annb smm arb
pD1 87.5            102.1             52.0
pD2 185.2            222.5           136.3
pD3/4 52.8              71.1             37.4
aDetermined by the Immune Epitope Database and Analysis 
Resource T cell epitope prediction tool for peptide binding 
to HLA-A*1101
bMHC class I binding prediction methods: ann=Artificial 
neural network, smm=Stabilized matrix method, 
arb=Average relative binding
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E. A11-NS3133 peptide variants elicit a hierarchy of functional responses from 
epitope-specific CD8+ T cells  
We next wanted to determine whether cytokine response profiles of individual 
CD8+ T cell lines correlated with lytic activity.  Therefore, we assessed degranulation and 
cytokine expression following stimulation with different concentrations of homologous 
and heterologous peptides in intracellular cytokine staining (ICS) assays (Figures 4.5 and 
4.6).  ICS of the pD1 serotype-specific cell line 10E11 revealed a robust response to high 
concentrations of homologous peptide; most cells up-regulated all four effector functions 
studied: degranulation (CD107a staining) and production of MIP-1β, TNFα, and IFNγ 
(Figure 4.5B).  Conversely, stimulation with pD2 resulted in no detectable response.  
Stimulation with pD3/4 caused a low percentage of CD8+ T cells to respond.  Of the 
responding T cells, most only produced MIP-1β, fewer cells were MIP-1β+CD107a+, and 
even fewer were MIP-1β+CD107a+TNFα+; no cells produced IFNγ. 
Stimulation of pD1-3/4 cross-reactive cell lines (as shown for the representative 
line 10C11 in Figure 4.5C) with either pD1 or pD3/4 induced nearly all CD3+CD8+ cells 
to respond, and a majority of cells in the culture expressed all four effector functions.  On 
the other hand, pD2 stimulation induced a low percentage of cells to respond, most of 
which only produced MIP-1β.  Akin to the cytolytic response, most cells of pD1-2-3/4 
cross-reactive cell lines (represented by 10B8 in Figure 4.5D) responded with all four 
effector functions upon stimulation with any of the three peptide variants. 
Regardless of a cell line’s recognition of different peptide variants, its response to 
stimulation exhibited a hierarchical induction of MIP-1β > degranulation > TNFα >  
FIGURE 4.5. Hierarchical response of effector functions in epitope-specific T cells.
(A) Gating strategy and representative flow plots of a cell line in response to the absence or presence of agonist peptide.  (B) pD1 serotype-
specific, (C) pD1-3/4 cross-reactive, and (D) pD1-2-3/4 cross-reactive cell lines were stimulated with each of the A11-NS3133 peptide 
variants in intracellular cytokine staining assays.  All possible combinations of the four effector functions (MIP-1β [M], TNFα [T], and 
IFNγ [I] production as well as degranulation [C], as determined by CD107a staining) are displayed across the x axis and grouped according 
to the number (#) of effector functions exhibited.  Mean frequencies of responding CD8+ T cells of 10E11 (n = 2), 10C11 (n = 4), and 10B8 
(n = 2) are shown.  Peptide concentrations are shown in µg/mL.
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Figure 4.6. Different epitope-specific T cell lines show similar effector responses.
Line graphs show the frequency of CD8+ T cells from five A11-NS3133-specific T cell lines that 
responded to peptide stimulation in ICS assays by degranulation (CD107a; red) or production of 
MIP-1β (blue), TNFα (green), or IFNγ (purple).  Data is shown as mean standard error and is 
relative to responses detected with no stimulation.  Peptide concentrations were 10, 1, 0.1, and 
0.01µg/mL. The name of each cell line is located to the top-left-hand side of the respective graph.
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IFNγ, as evidenced by its peptide-dose response curve.  With decreasing concentrations 
of agonist peptide (for example, pD1 and pD3/4 for the cell line 10C11), the effector 
response changed.  As the overall frequency of responding cells decreased, their 
distribution shifted toward exhibiting fewer effector functions, in particular loss of IFNγ 
and TNFα expression to primarily producing MIP-1β.  Below a critical concentration of 
agonistic peptide MIP-1β production also dropped off, as demonstrated by low 
concentrations of a partial agonist peptide (for example, pD2 for the cell line 10C11).  
Data were consistent for multiple epitope-specific T cell lines (Figure 4.6) and suggested 
that a signal threshold is required to generate a polyfunctional effector response.   
 
F. Cytokine responses induced by all three A11-NS3133 epitope variants are 
susceptible to cyclosporine A. 
To initiate an effector response, peptide-MHC complexes engage the TCR, which 
then initiates a series of protein phosphorylation events.  The TCR is a part of the CD3 
complex which also includes the ζ chain, one of the first proteins to become 
phosphorylated after pMHC-TCR engagement (refer to Introduction and Figure 1.1).  
This allows Zap70 to become activated and recruit other proteins which continue the 
phosphorylation cascade.  Two major pathways are involved (calcium and MAP kinase) 
which ultimately activate transcription factors (NFκB, NFAT and AP-1) that initiate the 
transcription of immune response genes.  Due to the different responses induced by pD2, 
compared to pD1 or pD3/4 (in pD1-3/4 cross-reactive T cell lines), we wanted to 
determine whether pD2 signaled via a pathway distinct from the other variants.  To do  
FIGURE 4.7. Cytokine responses, but not degranulation, elicited by all three A11-NS3133
epitope variants are susceptible to cyclosporine A.
(A) Representative flow plots show the response of the cell line 10C11 to no stimulation (NS) or 
stimulation with pD1 in the presence or absence of cyclosporine A (CSA).  (B) Bar graphs show 
the dose-dependent effect of CSA on degranulation (CD107a; green) and the production of MIP-1β 
(blue), TNFα (purple), and IFNγ (orange) by 10C11.  The concentration of CSA is shown as µM.
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this, we pre-treated T cells with cyclosporine A (CSA), a drug known to inhibit the 
calcium pathway by binding calcineurin and preventing it from activating NFAT (Shaw, 
et al., 1995).  CSA-treated T cells (10C11, pD1-3/4 cross-reactive) showed a dose-
dependent decrease in their production of IFNγ, TNFα, and MIP-1β in ICS assays, 
whereas degranulation was minimally affected (Figure 4.7).  These data indicate that 
cytokine responses elicited by these three dengue epitope variants all require NFAT 
activation, while the signal for degranulation is largely NFAT-independent. 
 
G. Phosphorylation of ERK1/2 correlates with cytolysis, degranulation, and 
induction of TNFα and IFNγ but not MIP-1β production 
To determine whether other pathways are involved in signaling after stimulation 
with each of the peptide variants, we utilized phosphoflow, a technique developed by 
Perez, et al. (Perez, et al., 2005).  Phosphoflow allows for the identification of 
phosphorylated proteins downstream of TCR signaling by flow cytometry.  We first 
needed to optimize protocol conditions to accommodate stimulation of T cell lines by 
viral peptides (Figure 4.8).   
We began by testing whether antigen presenting cells were necessary to help 
present exogenous peptide and induce robust phosphorylation of ERK1/2, a MAP kinase 
family member (refer to Figure 1.1).  We used different concentrations of peptide in the 
presence or absence of antigen presenting cells using a previously established T cell 
clone specific for the influenza virus (Flu) M158-66 peptide.  Levels of phosphorylated 
ERK1/2 (pERK1/2) were higher in T cells that were incubated with BLCL than in those  
FIGURE 4.8. Optimization of the phosphoflow protocol. 
(A) Gating strategy used to identifiy T cells for their expression of pERK1/2.  (B) T cells with or 
without BLCL were stimulated in the presence (blue) or absence (black) of peptide for 10 minutes 
in a 37 C water bath to induce the phosphorylation of ERK1/2.  (C) The Flu M158-specific T cell 
clone together with autologous BLCL and peptide was pre-incubated, or not, on ice for 30 minutes 
prior to being placed in the water bath as above.  (D) The DENV NS3529-specific T cell line 1C2 
up-regulates pERK1/2 upon stimulation with peptide variants derived from all four DENV 
serotypes.  Numbers in black indicate the frequency of pERK1/2+CD8+ T cells.  Percent specific 
lysis as determined by 51Cr-release assay at an effector-to-target ratio of 25:1 is also shown (orange 
numbers).  NS = no stimulation. 
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that were not, demonstrating the requirement of antigen presenting cells for robust 
peptide stimulation of a T cell line (Figure 4.8B).  Because of the short incubation period 
required for detection of pERK1/2 (10 minutes), we questioned whether pre-incubation of 
T cells, antigen presenting cells, and peptide (on ice) would enhance the pERK1/2 signal 
by allowing cell-cell contacts to form before placing them into a 37°C water bath to 
enable kinase activity.  T cells that were pre-incubated with BLCL and peptide on ice for 
30 minutes had higher levels of pERK1/2 than those that were not pre-incubated (Figure 
4.8C).  We also tested whether cytokine- or serum-starvation of T cells would ensure low 
background levels of pERK1/2 but found no differences regardless of T cell culture 
conditions (data not shown).  We next tested our protocol on a CD8+ T cell line 
previously established in our lab (1C2; generated by Pra-On Supradish, unpublished data) 
and specific for a DENV epitope (NS3529-537) and found that we could measure DENV-
specific, peptide-induced pERK1/2 (Figure 4.8D).  Similar to its ability to lyse peptide-
coated BLCL, 1C2 demonstrated comparable induction of pERK1/2 after stimulation 
with epitope variants derived from all four DENV serotypes. 
Stimulation of three representative A11-NS3133-specific T cell lines with 
increasing concentrations of agonist peptide resulted in a dose-dependent increase of 
pERK1/2 (Figure 4.9).  The phosphorylation of ERK1/2 correlated with the induction of 
cytolysis, degranulation, and TNFα and IFNγ production detected in ICS assays.  This 
was not the case for MIP-1β production, however, which was observed under conditions 
that failed to demonstrate ERK1/2 phosphorylation.  For instance, pD1 or pD3/4 
stimulation of the pD1-3/4 cross-reactive cell line 10C11 resulted in increased pERK1/2.   
FIGURE 4.9. Phosphorylation of ERK1/2 does not correlate with MIP-1β production. 
(A) Peptide dose-dependent phosphorylation of ERK1/2 after stimulation with epitope variants.  
(B) Average fold change in geometric mean fluorescence intensity (gMFI) of pERK1/2 in the cell 
lines 10E11 (n = 3), 10C11 (n = 4), and 10G5 (n = 2) after stimulation with decreasing 
concentrations (10, 1, 0.1, 0.01μg/mL) of the three peptide variants.  Fold change is relative to ‘no 
stimulation’ control.
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However, pD2 stimulation of 10C11, which up-regulated MIP-1β in ICS assays, failed to 
phosphorylate ERK1/2.   
 
H. The DENV-2 A11-NS3133 epitope variant acts as a partial agonist 
Our data so far have indicated that the pD1 and pD3/4 epitope variants are strong 
agonists able to induce robust T cell responses using both the calcium and MAP kinase 
signaling pathways.  As pD2 also signals through the calcium pathway, we speculated 
that pD2 stimulation may induce a delayed pERK1/2 signal which prevented us from 
detecting it in our previous assays.  Therefore we assessed pERK1/2 at 5, 10, 20, and 30 
minutes following stimulation of the pD1-3/4 cross-reactive cell line 10C11 with pD2.  
We were unable to detect up-regulation of pERK1/2, however, at any time point after 
pD2 stimulation (Figure 4.10A).  We next assessed phosphorylation of CD3ζ, a more 
proximal signal, to confirm that pD2 was specifically engaging the TCR.  After three 
minutes of stimulation, we detected phosphorylated CD3ζ (pCD3ζ) in response to each 
of the three epitope variants (Figure 4.10B).  The extent of pCD3ζ was comparable for all 
three dengue variants and was higher than that for a control (non-dengue) HLA-A*1101-
restricted peptide. 
We next analyzed expression of the activation marker CD137 as a further 
indicator of antigen-specific stimulation (Wolfl, et al., 2007) to confirm the specificity of 
the relatively small pD2 response by 10C11.  At 6 hours after stimulation, pD2 activated 
a low frequency of T cells to up-regulate CD137 (Figure 4.10C), correlating with its 
induction of MIP-1β measured by ICS.  The pD2-induced CD137 expression was not  
FIGURE 4.10. pD2 induces a short-lived activation signal in a pD1-3/4 cross-reactive cell 
line.
(A) Time course of pERK1/2 after pD2 stimulation of the cell line 10C11.  One of 2 independent 
experiments is shown.  (B) Phosphorylation of CD3ζ after stimulation of 10C11 with each of the 
three peptide variants.  Histograms are shaded to emphasize the change in gMFI.  One of 3 
independent experiments is shown.  (C) Time course of CD137 expression after stimulation of 
10C11 with pD1, pD2, and a control non-dengue HLA-A*1101-restricted viral peptide.  The 
peptide concentration used for these experiments was 10µg/mL. NS = no stimulation.
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sustained at 24 hours, however, whereas stimulation with a full agonist peptide (pD1) 
induced robust up-regulation of CD137 at both 6 and 24 hours.  These data indicated that 
pD2 was a partial agonist for 10C11, initiating calcium signaling but failing to up-
regulate pERK1/2.  This weak stimulus thus induced a short-lived signal that was only 
able to stimulate MIP-1β production but not degranulation, IFNγ, or TNFα. 
 
I. Chapter summary 
To further define the CD8+ T cell response to heterologous DENV serotypes, we 
assessed functional responses after short-term bulk culture and isolated HLA-A*1101-
restricted NS3133 epitope-specific CD8+ T cell lines from subjects who had primary 
DENV infections.  These T cell lines exhibited marked cross-reactivity toward epitope 
variants representing the four DENV serotypes in pMHC tetramer binding and functional 
assays.  Many clones responded similarly to homologous and heterologous serotypes with 
striking cross-reactivity between the DENV-1 and DENV-3 epitope variants.  In vitro-
stimulated T cell lines consistently revealed a hierarchical induction of MIP-1β > 
degranulation > TNFα > IFNγ, which depended on the concentration of agonistic peptide.  
Phosphoflow assays showed peptide dose-dependent phosphorylation of ERK1/2, which 
correlated with cytolysis, degranulation, and induction of TNFα and IFNγ, but not MIP-
1β production.  We also show qualitatively different T cell receptor signaling after 
stimulation with homologous and heterologous peptides; in particular, pD2 can act as a 
partial agonist.  By showing that different effector responses can be elicited from T cells 
depending on the epitope variant used for stimulation, these data support a model 
 116 
whereby the order of sequential DENV infections influences the immune response to 
secondary heterologous DENV infection, contributing to varying disease outcomes. 
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CHAPTER V 
DISCUSSION 
 
Plasma leakage, a hallmark of severe dengue disease, occurs late after infection 
and is coincident with viral clearance.  This, together with evidence that increased disease 
severity is associated with secondary heterologous DENV infection, suggests the 
involvement of cross-reactive DENV-specific memory T and B cells in contributing to an 
immunopathologically-mediated clinical outcome. 
We studied the frequency, kinetics, serotype-specificity, phenotype and function 
of DENV epitope-specific T cells during and/or after acute infection.  In comparison with 
previous studies, our study involved large cohorts of subjects with DF and DHF, uniquely 
distinguished between those with primary and secondary DENV infections, included 
infections with all four DENV serotypes and analyzed responses to immunodominant 
epitopes for two different HLA class I alleles, including detailed analyses of T cell 
functional responses to heterologous epitope variants.  Thus, our data address several 
gaps in the current literature, test the validity of assumptions underlying the interpretation 
of previous data and reveal new observations relevant to our understanding of dengue 
pathology. 
 
A. Antigen-specific T cell frequencies in acute primary versus secondary infection 
Mongkolsapaya et al. reported low but detectable frequencies of A11-NS3133-
specific T cells during acute secondary DENV infection in Thai children which peaked in 
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early convalescence (Mongkolsapaya, et al., 2003).  In contrast, Dung et al. recently 
reported that A11-NS3133-specific T cells were undetectable during the febrile phase until 
after the development of DHF among infected Vietnamese children (Dung, et al., 2010).  
Our data are clearly more consistent with the earlier report, and, in fact, several of our 
subjects had very high frequencies of epitope-specific T cells during acute infection, prior 
to the onset of plasma leakage, supporting their potential to contribute to disease 
pathogenesis.  Our data using the B7-NS3222 tetramer further confirmed this result, and 
are consistent with limited data from a previous study from our laboratory using IFNγ 
ELISPOT assays (Zivna, et al., 2002).  The finding of antigen-specific T cell expansion 
during viremia is also more consistent with observations in other viral diseases (Miller, et 
al., 2008; Akondy, et al., 2009; Wiesel, et al., 2009) and with other evidence of T cell 
activation during acute DENV infection (Kurane, et al., 1991; Green, et al., 1999a; Chau, 
et al., 2008).  The divergent findings of Dung et al. may reflect differences in 
experimental technique; a more intriguing possibility is that the expansion of A11-
NS3133-specific T cells differs between Thai and Vietnamese patients.  In this regard, it is 
of interest that an association with dengue disease severity has been observed for HLA-
A11 in our Thai cohort (Stephens, et al., 2002), but was not noted in a study in Vietnam 
(Nguyen, et al., 2008) despite the similar genetic backgrounds of these two populations. 
We found that the frequency of epitope-specific T cells peaked earlier in subjects 
with primary infection than in those with secondary infection.  Prior studies in which 
DENV-specific T cells were tracked over time had not differentiated between subjects 
with primary and secondary infections.  Given the more rapid proliferation of memory T 
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cells, and the more rapid clearance of viremia in secondary infection (Vaughn, et al., 
2000), this result was not anticipated but is consistent with findings in DENV infection of 
BALB/c mice (Beaumier, et al., 2008).  More rapid activation of memory T cells would 
not necessarily correspond to an earlier peak T cell frequency, since sustained 
proliferation signals balanced by apoptosis (Mongkolsapaya, et al., 2003; Myint, et al., 
2006) would affect the timing of peak responses to a greater extent.  Future studies need 
to incorporate analysis of these mechanisms as well as other immunomodulatory signals 
such as regulatory T cells (Luhn, et al., 2007). 
 
B. Lack of correlation between T cell frequency, activation and disease severity 
The magnitude of A11-NS3133-specific T cells did not correlate with disease 
severity in our cohort.  This held true whether the data were analyzed according to 
clinical diagnosis (i.e. DF versus DHF) or continuous measures of disease severity such 
as pleural effusion index, hemoconcentration, or platelet nadir.  A similar lack of 
association was reported in a study in Vietnam (Dung, et al., 2010).  Other studies had 
reported higher frequencies of DENV-specific T cells in patients with DHF, but these 
associations were found at 2 weeks (Mongkolsapaya, et al., 2003; Mongkolsapaya, et al., 
2006) or 6 months (Zivna, et al., 2002) post-infection.  Differences in timing or 
differences in infection history (i.e. serotype of primary and secondary infection) may 
explain the differences in results between these studies.  However, the lack of a 
correlation with disease severity and the timing of peak tetramer-positive T cell 
frequencies in early convalescence rather than at the time of plasma leakage (for at least 
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some subjects) indicate that the frequency of A11-NS3133 tetramer-positive T cells is not 
the principal determinant of disease.  T cell responses to other DENV epitopes may be 
more important contributors to disease, as is suggested by our limited data on B7-NS3222-
specific T cells in HLA-A11-B7+ subjects.  Alternatively, characteristics of the DENV-
specific T cell response other than quantity, for example effector responses (Bashyam, et 
al., 2006), may determine its immunopathological contribution.   
Our data on expression of phenotypic markers by tetramer-positive T cells 
demonstrated selective activation of DENV-specific T cells as well as a transition from 
an effector to a memory phenotype, consistent with findings in other acute human viral 
infections (Miller, et al., 2008; Akondy, et al., 2009).  There were no significant 
correlations between expression of activation or phenotypic markers and disease severity 
in this cohort.  This stands in contrast to the results of other studies focused on CD69, an 
early marker of activation (Green, et al., 1999a; Chau, et al., 2008).  We did observe 
slightly higher CD38 expression and a slightly earlier downregulation of CD45RA on 
tetramer-positive T cells during acute infection in secondary DENV infections compared 
to primary infections, which may reflect the expansion of pre-existing memory T cells.  
 
C. The presence of serotype-cross-reactive T cells in primary DENV infection 
Mongkolsapaya et al. found that A11-NS3133-specific T cells in patients with 
secondary DENV infections preferentially stained with pMHC tetramers corresponding 
to DENV serotypes heterologous to the infecting serotype and interpreted this result to 
demonstrate original antigenic sin (Mongkolsapaya, et al., 2003).  Our study used a 
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similar approach, but extended this analysis to primary DENV infections, an important 
comparison group absent in the earlier study.  Our ex vivo pMHC tetramer staining 
results demonstrated similar patterns of serotype-cross-reactive T cells in subjects with 
primary and secondary DENV infections, including cells with preferential binding of 
heterotypic tetramers.  Functional assays performed both ex vivo and on numerous A11-
NS3133-specific T cell lines isolated from patient PBMC confirmed the presence of 
extensive serotype-cross-reactivity in primary infection.  Thus, heterotypic tetramer 
binding in these subjects does not reflect a history of prior infection with other DENV 
serotypes; other possible explanations for this phenomenon are heterologous immunity 
from prior unrelated infections (Welsh, et al., 2010), private specificity of the T cell 
repertoire (Welsh, et al., 2006), or inherent immunogenicity of different epitope variants 
(Bashyam, et al., 2006; Beaumier, et al., 2008).  Despite great donor-to-donor variability, 
we noted some similarities in patterns of tetramer staining among individuals with the 
same infection status (i.e. DENV serotype, primary versus secondary).  This suggests that 
the sequence of infection is a factor in shaping the DENV-specific memory T cell 
repertoire, but other elements are more important for this epitope. 
Our in vitro findings support the notion that the order of DENV serotypes with 
which a particular individual is infected plays a role in the outcome of the secondary 
immune response.  The data suggest that, for the response to the A11-NS3133 epitope, 
DENV-1 infection followed by DENV-3 infection, or vice versa, would trigger the 
activation of cross-reactive T cells that undergo a vigorous polyfunctional response 
involving IFNγ production.  On the other hand, a secondary DENV-2 infection may elicit 
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cross-reactive, poorly responding T cells that are skewed toward MIP-1β production.  
Increased MIP-1β at the site of infection may augment IFNγ and TNFα production by T 
cells (Lillard, et al., 2003) activated by other viral epitopes and increase TNFα 
production by monocytes (Nath, et al., 2006), elevating the circulating levels of these 
cytokines and ultimately contributing to immunopathology.  Secondary DENV-2 
infection has been observed as a risk factor for increased disease severity in 
epidemiological studies in Asia (Guzman, et al., 1990; Thein, et al., 1997).   
While most severe cases of dengue are seen in patients experiencing a secondary 
DENV infection, many occur in infants experiencing a primary DENV infection.  This 
was often attributed solely to antibody-mediated enhancement of infection, but serotype-
cross-reactive T cell responses might contribute to severe disease in these cases as well.  
A pool of DENV-specific memory T cells presumably does not yet exist in the first year 
of life.  However, our data suggest that primary infection can elicit a large proportion of 
serotype-cross-reactive T cells.  Such a mix of responding T cells with a variety of 
affinities toward multiple DENV serotypes means that the serotype of infection holds 
great sway over the magnitude and type of T cell response induced.  Thus, our data 
indicate that the anti-DENV T cell response may play a greater role in dengue 
pathogenesis than previously appreciated.   
 
D. Differences between epitope variants  
We found that A11-NS3133 epitope-specific CD8+ T cell lines isolated from 
primary DENV immune donors were highly cross-reactive and demonstrated greater 
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recognition of pD1 and pD3/4 variant peptides as compared to pD2, consistent with ex 
vivo tetramer staining and limited functional data.  Dong et al. also detected significant 
pD1-3/4 cross-reactivity within this A11 epitope-specific T cell population after 
secondary DENV infection (Dong, et al., 2007).  Though a different DENV-2 epitope 
variant was used in that study, a majority of their ‘highly cross-reactive’ T cell clones 
recognized pD1 and pD3/4 with greater potency than the DENV-2 variant.   
The predominance of pD1-3/4 cross-reactivity may be explained by the primary 
structure of these epitope variants.  Classic A11-restricted epitopes have a small aliphatic 
residue at position 2 (P2) and a basic residue at the C terminus (Kubo, et al., 1994; 
Sidney, et al., 1996; Sidney, et al., 2008).  The epitope used in our study follows this 
motif since it contains a threonine at P2 as well as a C-terminal arginine.  Recently, a 
secondary anchor residue for A11-restricted epitopes was identified at P6 or P7, which 
creates a double bulge of neighboring amino acids exposing likely sites of TCR contact 
(Li and Bouvier, 2004).  Such bulging of the A11 dengue epitope would expose P9, the 
residue that differs between pD1 or pD3/4 and pD2.  However, P9 of a 10-mer epitope 
from HIV was determined to be the C-terminal MHC anchor residue (Couillin, et al., 
1994).  No matter which side of the TCR-MHC interface interacts with the P9 residue, 
the non-conservative amino acid change (and corresponding charge difference) between 
pD1 or pD3/4 (asparagine) and pD2 (aspartate) could drastically affect binding avidity.  
These epitope variants have been crystallized together with HLA-A*1101 
(Chotiyarnwong, et al., 2007), which indicates tight binding of peptide and MHC.  
However, three different algorithms predicted that A11 binding for the three peptide 
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variants reflects a hierarchy of pD3/4>pD1>>pD2.  We speculate that poor binding of 
pD2, compared to pD1 and pD3/4, to either A11 or the TCR may explain its lower 
functional avidity apparent in our study, consistent with the ‘induced fit’ or ‘antigen-
dependent tuning of peptide-MHC flexibility’ mechanisms of cross-reactivity (Yin and 
Mariuzza, 2009).   
 
E. Discordance in the epitope variant hierarchy between pMHC tetramer binding 
and functional avidity 
The hierarchical preference of pD1>pD3/4>pD2 detected when cells were directly 
stained ex vivo with pMHC tetramers was similarly detected after short-term bulk culture 
of peptide-stimulated patient PBMC as well as for individual epitope-specific T cell lines.  
However, functional assays suggested that pD3/4 was a better agonistic ligand than pD1, 
supporting their predicted MHC binding affinity hierarchy of pD3/4>pD1>pD2.  This 
was evidenced by the different peptide dose response curves in 51Cr release and ICS, 
though not phosphoflow, assays performed on the isolated T cell lines.  Other studies 
have shown a similar discordance between T cell function and pMHC tetramer binding 
by antigen-specific T cells (Derby, et al., 2001; Kalergis, et al., 2001; Rubio-Godoy, et 
al., 2001; Dutoit, et al., 2002) and suggested that pMHC tetramer dissociation assays 
were a better predictor of functional avidity than direct binding (Rubio-Godoy, et al., 
2001; Dutoit, et al., 2002).  Kalergis et al. used point mutations to show that TCR-pMHC 
engagement had to be sufficiently long to allow for efficient T cell activation and that too 
long (or too short) of an interaction could compromise the “agonist potency of pMHC 
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variants” (Kalergis, et al., 2001).  Our data fit this model in that the hierarchy of 
functional avidity (pD3/4>pD1>pD2) was evident in assays that required a long 
incubation time (i.e. 51Cr release and ICS) but was obscured (pD1>pD3/4>pD2) in assays 
with short incubation times (i.e. pMHC tetramer binding and phosphoflow).  Thus, the 
extent of serotype-cross-reactivity detected by pMHC tetramer staining of PBMC ex vivo 
might underestimate the true functional serotype-cross-reactive potential of A11-NS3133 
epitope-specific T cells. 
 
F. Functional similarities of epitope-specific T cells 
 Regardless of their serotype-cross-reactivity, the functional response of all the 
A11-NS3133-specific CD8+ T cell lines we tested revealed a hierarchical induction of 
MIP-1β > degranulation > TNFα > IFNγ.  This is in line with a recent report from our 
laboratory characterizing PBMC from DENV vaccinees in response to in vitro 
stimulation of homologous and heterologous HLA-A*0201-restricted epitope variants 
(Bashyam, et al., 2006).  Imrie et al., however, found that a larger proportion of CD8+ T 
cell clones specific for a B*5502-restricted epitope on the DENV NS5 protein produced 
IFNγ compared to TNFα (Imrie, et al., 2007).  Studies of HIV-specific T cells 
demonstrated a hierarchical induction of MIP-1β > degranulation > IFNγ > TNFα > IL-2 
(Betts, et al., 2006; Ferre, et al., 2009).  Patients who were better able to control their 
HIV viral loads had higher numbers of T cells exhibiting multiple effector functions in 
both PBMC (Betts, et al., 2006) as well as rectal mucosa (Ferre, et al., 2009), suggesting 
a protective role for polyfunctional CD8+ T cells.  While the hierarchical induction of 
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MIP-1β > degranulation > cytokines in virus-specific CD8+ T cells was observed in all of 
these studies, it is unclear what factors affect the particular order of cytokine production.  
The fact that A11-NS3133-specific T cells appear to initiate TNFα production before IFNγ 
production may suggest their predisposition toward secreting immunopathogenic 
(TNFα), as opposed to protective (IFNγ), cytokines.  In this regard, it is important to note 
that HLA-A11 is reported to have a modest association with severe disease (Stephens, et 
al., 2002).   
Previous studies have shown that varying degrees of TCR-ligand interaction elicit 
a hierarchical order of response thresholds for different effector functions (Valitutti, et 
al., 1995; Valitutti, et al., 1996; Itoh and Germain, 1997; Hemmer, et al., 1998; Betts, et 
al., 2004; La Gruta, et al., 2004).  It was determined that, regardless of ligand potency, 
the extent of TCR engagement as measured by TCR down-regulation dictated the 
functional response elicited from the T cell.  Specifically, cytotoxicity was elicited after 
very low levels of TCR occupancy by peptide-MHC whereas cytokine responses required 
higher occupancy for induction.  Our data support these findings in that cytotoxicity 
(measured by target cell lysis and degranulation) was induced at the lowest 
concentrations of full agonist peptides used as well as high concentrations of partial 
agonist peptides.  TNFα and IFNγ production was only seen after stimulation with full 
agonist peptides, and the proportion of cells producing these cytokines increased with 
increasing concentrations of those peptides, supporting the idea that greater TCR 
occupancy triggers cytokine production.  Additionally, phosphoflow assays performed in 
our study confirmed that low TCR occupancy qualitatively altered peptide-induced 
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signaling pathways (i.e. pD1 and pD3/4 induced pERK1/2 whereas pD2 did not), which 
helps explain differential effector responses.  This is the first time phosphoflow has been 
utilized to demonstrate variations in peptide-induced signaling in T cells, and it has 
proven to be an effective tool for measuring such differences.  Altogether our data argue 
that production of the chemokine MIP-1β has an even lower signal threshold than 
cytotoxicity, supporting other studies which suggest MIP-1β is a more sensitive measure 
of antigen-specific cells than IFNγ (De Rosa, et al., 2004; Betts, et al., 2006). 
The polyfunctional nature of the effector responses we detected from epitope-
specific CD8+ T cell lines was not necessarily reflected in ICS responses detected ex vivo.  
Many responses from subjects with primary infection were dominated by a single effector 
function, though this was less evident in responses from subjects with secondary 
infection.  Other studies have noted the prevalence of mono- or oligo-functional 
responses detected ex vivo (Bashyam, et al., 2006; Duangchinda, et al., 2010).  The 
samples we used for ex vivo stimulation were taken within one week after defervescence, 
indicating that T cells detected in subjects with primary infection have not yet 
differentiated into memory T cells.  This may explain the lower frequency of 
polyfunctional T cells in these subjects versus those with secondary infection, as memory 
T cells more rapidly induce multiple effector functions simultaneously compared to naïve 
T cells (Zimmermann, et al., 1999; Veiga-Fernandes, et al., 2000).  
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G. Study limitations 
The interpretation of our data is subject to several limitations.  Although the 
patient cohort used for ex vivo analysis was relatively large, the small number of HLA-
A11+ subjects with the same DENV serotype, serologic response (primary/secondary 
infection), and clinical outcome (DF/DHF) limits the statistical power for important 
subgroup analyses, and data from HLA association studies suggest that the influence of T 
cell responses may not be the same for all four serotypes (Stephens, et al., 2002).  
Additionally, although subjects were followed daily during acute illness, adequate 
specimens were not available for all of these flow cytometry studies from all time points 
for all subjects.  Given that rapid changes were observed in tetramer-positive T cell 
frequencies during acute infection, it is likely that peak frequencies were missed in some 
subjects.  Furthermore, some PBMC had very high frequencies of epitope-specific T 
cells, but we were not able to reconfirm the data due to limited sample volume, leading us 
to interpret the results with caution.  However, repeat staining of selected samples where 
we had multiple vials gave consistent results.  Few of the DHF patients in our study 
experienced shock (i.e. DHF grades III or IV).  As Mongkolsapaya et al. found the 
highest frequencies of tetramer-positive T cells in patients with shock (Mongkolsapaya, 
et al., 2003; Mongkolsapaya, et al., 2006), it is possible that the milder disease in our 
study cohort concealed a relationship to the most severe disease.  Moreover, while our 
study is the first to assess T cell responses to more than one DENV epitope within 
individual subjects, we cannot exclude the possibility that these epitopes are not 
representative of the global DENV-specific CD8+ T cell response.  Duangchinda et al. 
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recently showed higher cytokine responses in children with DHF compared to DF when 
overlapping peptides covering the entire NS3 protein were used (Duangchinda, et al., 
2010).  However, that study only analyzed PBMC collected several weeks post-infection 
and the same association was not detected by Simmons et al. (Simmons, et al., 2005a).  
Finally, human studies are limited to analysis of blood samples, and we may have missed 
pathogenic T cells that were bound to the endothelium or located in other tissues. 
Our study was also limited to characterizing CD8+ T cell lines specific for a single 
epitope, whereas the overall T cell response would reflect responses to multiple epitopes 
with varying patterns of serotype-cross-reactivity.  Our limited ex vivo analysis of B7-
NS3222-specific T cells in HLA-A11+B7+ versus A11-B7+ subjects suggested a possible 
influence of particular HLA haplotypes on the expansion of epitope-specific T cells.  
Future analyses should investigate whether the immunodominance hierarchy of epitope-
specific T cells is maintained in subjects with varying combinations of HLA alleles.  Our 
cell line study was ultimately limited to four patients, but the subjects did vary with 
regard to the infecting serotype, age, illness grade as well as genetic background.  We 
isolated many T cell lines from each patient that showed similar patterns of serotype-
cross-reactivity to the A11-NS3133 epitope.  Further functional studies on individuals 
infected with other DENV serotypes, experiencing different illnesses and who have 
different genetic backgrounds than our donors will add to our understanding of the 
contribution of this and other cross-reactive epitope-specific T cell populations to disease.   
In addition to lifelong immunity to the currently-infecting serotype, primary 
DENV infection induces transient but protective immunity to heterologous DENV 
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serotypes in patients for at least two months after illness (Sabin, 1952).  The patient 
samples from which we isolated epitope-specific T cell lines (and detected ex vivo 
functional responses) were collected eight months or less after primary infection.  It is 
possible that the cross-reactive T cell responses we observed might not represent stable, 
long term T cell memory.  Analysis of memory T cell responses after longer intervals 
would be complicated by the substantial potential for re-exposure to DENV in individuals 
living in DENV-endemic areas.  However, our group has detected serotype-cross-reactive 
T cell responses in vaccine recipients several years after immunization (Zivny, et al., 
1999; Mangada and Rothman, 2005; Bashyam, et al., 2006) suggesting that primary 
exposure to the virus generates a long-lived cross-reactive memory T cell response.   
 
H. Summary, implications, and revisions to the T cell immunopathogenesis model 
In summary, our data points to a complex picture of T cell involvement in DENV 
infection.  Specifically, this thesis showed: 
• a diverse pattern of serotype-cross-reactivity in both primary and secondary 
infections 
• selective activation and expansion of DENV-specific T cells during acute 
infection  
• kinetic differences in peak frequency and phenotypic evolution (i.e. CD45RA 
expression) of T cells in primary versus secondary DENV infection 
• no correlation between the magnitude of DENV tetramer-positive T cells and 
disease 
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• variable agonistic properties of different A11-NS3133 epitope variants 
These results alter the way we think about T cell involvement in dengue pathology. 
 Prior to DENV infection, the naïve T cell repertoire theoretically includes T cells 
with a variety of specificities for the four DENV serotypes.  Our group and others 
hypothesized that the pool of memory T cells generated during primary DENV infection 
largely comprises serotype-specific T cells with a smaller proportion of cells with low 
affinity to heterologous serotypes (Figure 5.1A and B).  Upon secondary heterologous 
DENV infection, for example DENV-3 infection following a prior DENV-1 infection, the 
memory T cells with low affinity to DENV-3 are preferentially re-activated (due to their 
lower threshold for activation compared to higher affinity, DENV-3 specific naïve T 
cells).  The low affinity interaction with heterotypic antigen (i.e. antigen from the 
currently infecting, heterologous serotype) elicits a sub-optimal T cell response (e.g. high 
TNFα production) that ultimately contributes to disease pathology.   
However, the data generated in this thesis suggest that serotype-cross-reactivity in 
the response to primary infection is much more extensive than previously appreciated 
(Figure 5.1C).  This changes our view of how T cells may be activated upon secondary 
infection.  T cells with high affinity for DENV-1 do not necessarily have low affinity for 
DENV-3, effectively increasing the pool of DENV-specific memory T cells available to 
respond in secondary heterologous infection (Figure 5.1D).  The serotype of the infecting 
virus in secondary infection then plays a greater part in determining the final T cell 
effector response, as the extent and position of amino acid changes within the epitope 
variant’s sequence will affect its ability to activate T cells.  Based on our data with A11- 
FIGURE 5.1. Revisions to the model of T cell involvement in dengue pathogenesis.
(A) Following a primary infection with any serotype of DENV, the majority of memory T cells 
generated are specific to the infecting serotype while a relatively small proportion of T cells are 
cross-reactive to other serotypes.  Each colored circle represents the T cell response for one of the 
four DENV serotypes.  The extent of serotype-cross-reactivity is shaded in black.  (B) The old 
model for T cell-mediated dengue pathogenesis indicates that T cells differ in their relative affinity 
for DENV serotypes (shown here for DENV-1 and -3).  The highest affinity T cells are activated in 
primary infection and transition to memory after viral clearance.  Upon secondary heterologous 
infection, low affinity, serotype-cross-reactive memory T cells have an advantage (in frequency 
and threshold for activation) over high affinity naïve T cells and mediate a skewed cytokine 
response which ultimately contributes to dengue pathology.  Each colored circle represents a single 
T cell clonotype.  Light colors indicate naïve/effector T cells; darker colors indicate memory T 
cells.  
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FIGURE 5.1. Revisions to the model of T cell involvement in dengue pathogenesis. (cont’d)
...(C) In our revised model, primary infection generates a greater proportion of memory T cells that 
are serotype-cross-reactive than previously appreciated.  Each colored circle represents the T cell 
response specific for one of the four DENV serotypes.  The extent of serotype-cross-reactivity is 
shaded in black.  (D) The revised model recognizes the presence of naïve T cells with a variety of 
serotype-specific affinities, which do not necessarily have low affinity for heterologous serotypes.  
The pool of T cells available for (re-)activation is thus larger than previously expected in both 
primary and secondary infection.  Based on our data regarding A11-NS3133-specific T cells, 
DENV-1 followed by DENV-3 or -4 infection might re-activate a response akin to that seen for 
DENV-1 infection, which includes IFNγ production, likely leading to protection from severe 
disease.  However, DENV-1 followed by DENV-2 infection might re-activate a smaller response 
(due to its partial agonist effect) which would be dominated by MIP-1β production, possibly 
leading to enhanced cytokine (e.g. TNFα) production by other nearby T cells or monocytes. Each 
colored circle represents a single T cell clonotype.  Light colors indicate naïve/effector T cells; 
darker colors indicate memory T cells. 
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NS3133 epitope-specific T cells, DENV-1 followed by DENV-3 infection might activate a 
comparable response to primary DENV-1 infection whereas secondary DENV-2 
infection might activate a weaker response that exhibits an altered functional profile (i.e. 
MIP-1β without IFNγ production). 
We believe that severe disease results when a combination of host genetics and 
viral factors add to an altered T and B cell profile in the host (Figure 5.2).  This thesis 
sought to better understand features of the T cell response that may contribute to dengue 
disease and found extensive serotype-cross-reactivity; responses are complex and can 
vary even for a single epitope.  Even if we consider proliferative and functional responses 
to two epitopes out of a given individual’s global anti-DENV T cell response, there are 
several possible outcomes.  Therefore, the role that T cells play in influencing dengue 
disease may be bigger than previously anticipated.  Ultimately, altered T cell responses 
elicited by heterologous variants of DENV together with the viral load, antibody 
response, host genetics and other factors determine disease outcome. 
   
FIGURE 5.2. Disease outcome is governed by a variety of factors.
DENV infection leads to one of many possible disease outcomes, which is governed by a variety of factors, including T cell responses.  Viremia 
affects the size and type of T cell response and vice versa.  The global T cell response (blue boxes) is a culmination of responses by T cells 
specific for multiple epitopes (shown here for any 2 epitopes; circles within each box).  Shown are possible responses by 2 epitope-specific T 
cell populations which can proliferate robustly or not (represented by the size of the circle) and exhibit a robust or limited effector response 
(represented by the number of different colors within each circle).  The effector profile of the T cells can also vary by magnitude of the response 
(represented by big or small trapezoid shapes) as well as type of response (the relative effect of cytolysis [CTL] and cytokine production is 
shown by size of lettering; a change in type of cytokine response [e.g. IFNγ>TNFα changing to TNFα>IFNγ] is represented by different colors).  
The antibody response, host genetic factors, and other variables also influence a patient’s final outcome, which ranges in severity from 
asymptomatic infection to shock and possible death.
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